T-cell	B-cell_type
-directed	O
TAL-1	B-protein
expression	O
induces	O
T-cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
TAL-1	B-DNA
gene	I-DNA
specifies	O
for	O
a	O
basic	O
domain-helix-loop-helix	B-protein
protein	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
control	O
of	O
normal	O
hematopoiesis	O
.	O

In	O
human	O
pathology	O
,	O
the	O
TAL-1	B-protein
gene	I-protein
product	I-protein
is	O
expressed	O
in	O
a	O
high	O
percentage	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
in	O
the	O
pediatric	O
age	O
range	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
established	O
whether	O
the	O
expression	O
has	O
a	O
causal	O
role	O
in	O
oncogenesis	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
phenotype	O
of	O
mouse	B-cell_line
transgenic	I-cell_line
lines	I-cell_line
obtained	O
by	O
inducing	O
tal-1	B-protein
protein	I-protein
expression	O
in	O
lymphoid	O
tissues	O
using	O
the	O
LCK	B-DNA
promoter	I-DNA
.	O

The	O
survival	O
rate	O
of	O
tal-1	B-DNA
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O

Histopathological	O
analysis	O
revealed	O
lymphomas	O
of	O
T-cell	O
type	O
,	O
often	O
comprising	O
a	O
minor	O
B-cell	O
component	O
.	O

Some	O
mice	O
showed	O
marked	O
splenic	O
lymphocyte	O
depletion	O
.	O

Primary	B-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
showed	O
partial	O
independence	O
from	O
exogenous	O
growth	O
stimuli	O
and	O
increased	O
resistance	O
to	O
low-serum	O
apoptosis	O
.	O

To	O
further	O
unravel	O
the	O
tal-1	B-DNA
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	B-DNA
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-/-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one-half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	B-DNA
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T-cell	B-cell_type
lymphomas	O
.	O

These	O
data	O
indicate	O
that	O
TAL-1	B-protein
,	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
is	O
per	O
se	O
a	O
potent	O
oncogene	O
,	O
which	O
may	O
exert	O
a	O
key	O
leukemogenetic	O
role	O
in	O
the	O
majority	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
56	NULL
,	NULL
5113-5119	NULL
,	NULL
November	NULL
15	NULL
,	NULL
1996	NULL
]	NULL
Advances	NULL
in	NULL
Brief	NULL
T-Cell-directed	NULL
TAL-1	NULL
Expression	NULL
Induces	NULL
T-Cell	NULL
Malignancies	NULL
in	NULL
Transgenic	NULL
Mice	NULL
'	NULL
G.	NULL
L.	NULL
Condorelli	NULL
,	NULL
``	NULL
F.	NULL
Facchiano	NULL
,	NULL
``	NULL
``	NULL
M.	NULL
Valtieri	NULL
,	NULL
E.	NULL
Proietti	NULL
,	NULL
L.	NULL
Vitelli	NULL
,	NULL
V.	NULL
Lulli	NULL
,	NULL
K.	NULL
Huebner	NULL
,	NULL
C.	NULL
Peschle	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Croce*	NULL
Kimmel	NULL
Cancer	NULL
Center	NULL
,	NULL
Jefferson	NULL
Medical	NULL
College	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pennsylvania	NULL
19107	NULL
[	NULL
G.	NULL
L.	NULL
C.	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
C.	NULL
P..	NULL
C.	NULL
M.	NULL
C.	NULL
]	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Hematology-Oncology	NULL
[	NULL
M.	NULL
V.	NULL
,	NULL
L.	NULL
V.	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
C.	NULL
P.	NULL
]	NULL
and	NULL
Department	NULL
of	NULL
Virology	NULL
[	NULL
E.	NULL
P.	NULL
]	NULL
,	NULL
Istituto	NULL
Superiore	NULL
di	NULL
Sanita	NULL
,	NULL
00161	NULL
Rome	NULL
,	NULL
Italy	NULL
Abstract	NULL
The	NULL
TAL-1	NULL
gene	NULL
specifies	NULL
for	NULL
a	NULL
basic	NULL
domain-helix-loop-helix	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
normal	NULL
hematopoiesis	NULL
.	NULL

In	NULL
human	NULL
pathology	NULL
,	NULL
the	NULL
TAL-I	NULL
gene	NULL
product	NULL
is	NULL
expressed	NULL
in	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
T-cell	NULL
acute	NULL
lymphoblastic	NULL
leukemias	NULL
in	NULL
the	NULL
pediatric	NULL
age	NULL
range	NULL
;	NULL
however	NULL
,	NULL
it	NULL
has	NULL
not	NULL
been	NULL
established	NULL
whether	NULL
the	NULL
expression	NULL
has	NULL
a	NULL
causal	NULL
role	NULL
in	NULL
oncogenesis	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
describe	NULL
the	NULL
phenotype	NULL
of	NULL
mouse	NULL
transgenic	NULL
lines	NULL
obtained	NULL
by	NULL
inducing	NULL
tal-1	NULL
protein	NULL
expression	NULL
in	NULL
lymphoid	NULL
tissues	NULL
using	NULL
the	NULL
LCK	NULL
promoter	NULL
,	NULL
The	NULL
survival	NULL
rate	NULL
of	NULL
tal-1	NULL
transgenic	NULL
animals	NULL
was	NULL
much	NULL
lower	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
mice	NULL
.	NULL

Histopathological	NULL
analysis	NULL
revealed	NULL
lymphomas	NULL
of	NULL
T-cell	NULL
type	NULL
,	NULL
often	NULL
comprising	NULL
a	NULL
minor	NULL
B-cell	NULL
component	NULL
.	NULL

Some	NULL
mice	NULL
showed	NULL
marked	NULL
splenic	NULL
lymphocyte	NULL
depletion	NULL
.	NULL

Primary	NULL
lymphocyte	NULL
cultures	NULL
showed	NULL
partial	NULL
independence	NULL
from	NULL
exogenous	NULL
growth	NULL
stimuli	NULL
and	NULL
increased	NULL
resistance	NULL
to	NULL
low-serum	NULL
apoptosis	NULL
.	NULL

To	NULL
further	NULL
unravel	NULL
the	NULL
tal-1	NULL
oncogenic	NULL
potential	NULL
,	NULL
a	NULL
strain	NULL
of	NULL
tal-1	NULL
transgenic	NULL
mice	NULL
was	NULL
crossbred	NULL
with	NULL
p53~'~	NULL
mice	NULL
;	NULL
the	NULL
survival	NULL
rate	NULL
in	NULL
these	NULL
animals	NULL
was	NULL
reduced	NULL
by	NULL
more	NULL
than	NULL
one-half	NULL
when	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
tal-1	NULL
mice	NULL
,	NULL
and	NULL
histopathological	NULL
analysis	NULL
revealed	NULL
exclusively	NULL
T-cell	NULL
lymphomas	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
TAL-1	NULL
,	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
is	NULL
per	NULL
se	NULL
a	NULL
potent	NULL
oncogene	NULL
,	NULL
which	NULL
may	NULL
exert	NULL
a	NULL
key	NULL
leukemogenetic	NULL
role	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
T-cell	NULL
acute	NULL
lymphoblastic	NULL
leukemias	NULL
.	NULL

Introduction	NULL
Transcription	NULL
factors	NULL
are	NULL
often	NULL
involved	NULL
in	NULL
tumorigenesis	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
TAL-	NULL
]	NULL
gene	NULL
(	NULL
also	NULL
known	NULL
as	NULL
SCL	NULL
or	NULL
TCL-5	NULL
)	NULL
,	NULL
identified	NULL
by	NULL
analysis	NULL
of	NULL
t	NULL
(	NULL
1	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p32	NULL
;	NULL
q11	NULL
)	NULL
translocations	NULL
in	NULL
human	NULL
T-ALL	NULL
,	NULL
Â°	NULL
codes	NULL
for	NULL
the	NULL
tai-1	NULL
protein	NULL
belonging	NULL
to	NULL
the	NULL
family	NULL
of	NULL
bHLH	NULL
domain	NULL
transcription	NULL
factors	NULL
(	NULL
3-5	NULL
)	NULL
,	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
TAL-/	NULL
gene	NULL
,	NULL
although	NULL
silent	NULL
in	NULL
normal	NULL
adult	NULL
T	NULL
lymphocytes	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
,	NULL
is	NULL
constitutively	NULL
activated	NULL
in	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
T-ALL	NULL
by	NULL
various	NULL
mechanisms	NULL
;	NULL
these	NULL
include	NULL
chromosomal	NULL
translocation	NULL
,	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
only	NULL
3	NULL
%	NULL
of	NULL
T-ALL	NULL
,	NULL
or	NULL
cis	NULL
events	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
specific	NULL
interstitial	NULL
chromosomal	NULL
deletions	NULL
affecting	NULL
the	NULL
5	NULL
'	NULL
noncoding	NULL
region	NULL
of	NULL
TAL-	NULL
]	NULL
leading	NULL
to	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
gene	NULL
in	NULL
approximately	NULL
25	NULL
%	NULL
of	NULL
T-ALL	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
recent	NULL
study	NULL
has	NULL
shown	NULL
that	NULL
TAL-	NULL
]	NULL
is	NULL
abnormally	NULL
expressed	NULL
in	NULL
the	NULL
leukemic	NULL
cells	NULL
of	NULL
most	NULL
patients	NULL
with	NULL
T-ALL	NULL
;	NULL
a	NULL
trans-acting	NULL
event	NULL
may	NULL
explain	NULL
the	NULL
active	NULL
TAL-/	NULL
transcription	NULL
in	NULL
T-ALL	NULL
cases	NULL
without	NULL
apparent	NULL
TAL-/	NULL
gene	NULL
alteration	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Altogether	NULL
,	NULL
Received	NULL
9/11/96	NULL
;	NULL
accepted	NULL
10/4/96	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Cancer	NULL
Institute	NULL
Outstanding	NULL
Investigator	NULL
Grant	NULL
CA39860	NULL
(	NULL
to	NULL
C.	NULL
M.	NULL
C.	NULL
)	NULL
and	NULL
Grant	NULL
CA21124	NULL
(	NULL
to	NULL
K.	NULL
H.	NULL
)	NULL
.	NULL

G.	NULL
L.	NULL
C.	NULL
is	NULL
the	NULL
recipient	NULL
of	NULL
an	NULL
AIDS	NULL
fellowship	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Health	NULL
,	NULL
Rome	NULL
,	NULL
Italy	NULL
.	NULL

2	NULL
Both	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

*	NULL
Present	NULL
address	NULL
:	NULL
Istituto	NULL
Dermopatico	NULL
dell	NULL
'	NULL
Immacolata	NULL
,	NULL
Lab	NULL
.	NULL

of	NULL
Vascular	NULL
Pathology	NULL
,	NULL
Via	NULL
Monti	NULL
di	NULL
Creta	NULL
104	NULL
,	NULL
00167	NULL
Rome	NULL
,	NULL
Italy	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Kimmel	NULL
Cancer	NULL
Center	NULL
,	NULL
Jefferson	NULL
Medical	NULL
College	NULL
,	NULL
233	NULL
South	NULL
10th	NULL
Street	NULL
,	NULL
BLSB	NULL
,	NULL
Room	NULL
1050	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
19107-5799	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
T-ALL	NULL
,	NULL
T-cell	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
;	NULL
bHLH	NULL
,	NULL
basic	NULL
helix-loop-helix	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
ConA	NULL
,	NULL
concanavalin	NULL
A	NULL
;	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcriptase	NULL
;	NULL
RT-PCR	NULL
,	NULL
reverse	NULL
transcription-PCR	NULL
;	NULL
GAPDH	NULL
,	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
.	NULL

TAL-1	NULL
seems	NULL
to	NULL
be	NULL
abnormally	NULL
expressed	NULL
in	NULL
>	NULL
60	NULL
%	NULL
of	NULL
T-ALL	NULL
cases	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
normal	NULL
tissues	NULL
,	NULL
tal-1	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
hematopoietic	NULL
CD34	NULL
*	NULL
progenitor	NULL
cells	NULL
and	NULL
erythroid	NULL
,	NULL
megakaryocytic	NULL
,	NULL
and	NULL
masto-cytic	NULL
lineages	NULL
(	NULL
12-14	NULL
)	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
tal-1	NULL
determines	NULL
a	NULL
block	NULL
of	NULL
early	NULL
blood	NULL
cell	NULL
formation	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
involving	NULL
all	NULL
hematopoietic	NULL
and	NULL
lymphoid	NULL
lineages	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
tal-1	NULL
favors	NULL
erythroid	NULL
development	NULL
,	NULL
whereas	NULL
its	NULL
expression	NULL
is	NULL
shut	NULL
off	NULL
in	NULL
granulopoietic	NULL
differentiation	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
main	NULL
structural	NULL
feature	NULL
of	NULL
the	NULL
tal-1	NULL
protein	NULL
is	NULL
the	NULL
bHLH	NULL
motif	NULL
,	NULL
which	NULL
includes	NULL
both	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
domains	NULL
;	NULL
particularly	NULL
,	NULL
the	NULL
TAL-/	NULL
bHLH	NULL
motif	NULL
has	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
homology	NULL
(	NULL
84	NULL
%	NULL
)	NULL
with	NULL
the	NULL
bHLH	NULL
domains	NULL
of	NULL
LYL-/	NULL
and	NULL
TAL-2	NULL
,	NULL
two	NULL
other	NULL
genes	NULL
occasionally	NULL
activated	NULL
by	NULL
chromosomal	NULL
translocation	NULL
in	NULL
T-ALL	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
tal-1	NULL
protein	NULL
heterodimerizes	NULL
with	NULL
products	NULL
of	NULL
the	NULL
Â£24	NULL
gene	NULL
;	NULL
the	NULL
heterodimer	NULL
preferentially	NULL
binds	NULL
to	NULL
a	NULL
sequence	NULL
containing	NULL
an	NULL
E-box	NULL
consensus	NULL
motif	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
tal-1	NULL
and	NULL
E2A	NULL
protein	NULL
heterodimers	NULL
are	NULL
present	NULL
in	NULL
T	NULL
leukemic	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
and	NULL
normal	NULL
erythroid	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
tal-1	NULL
in	NULL
leukemogenesis	NULL
is	NULL
still	NULL
debated	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
targeted	NULL
expression	NULL
of	NULL
tal-1	NULL
in	NULL
T	NULL
cells	NULL
through	NULL
a	NULL
transgene	NULL
under	NULL
a	NULL
CD2	NULL
enhancer	NULL
and	NULL
the	NULL
strong	NULL
SRa	NULL
viral	NULL
promoter	NULL
does	NULL
not	NULL
cause	NULL
tumors	NULL
(	NULL
24	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
in	NULL
transgenic	NULL
mice	NULL
,	NULL
TAL-1	NULL
driven	NULL
by	NULL
the	NULL
LCK	NULL
promoter	NULL
is	NULL
a	NULL
potent	NULL
oncogene	NULL
able	NULL
to	NULL
induce	NULL
T-cell	NULL
malignant	NULL
tumors	NULL
.	NULL

These	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
in	NULL
vitro	NULL
results	NULL
(	NULL
25	NULL
)	NULL
,	NULL
suggest	NULL
a	NULL
causal	NULL
role	NULL
of	NULL
TAL-	NULL
]	NULL
expression	NULL
in	NULL
T-ALL	NULL
leukemo-genesis	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Transgenic	NULL
Mice	NULL
C57BL/6	NULL
mice	NULL
and	NULL
p53	NULL
homozygous	NULL
recombinant	NULL
mice	NULL
were	NULL
purchased	NULL
from	NULL
The	NULL
Jackson	NULL
Laboratory	NULL
(	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
and	NULL
Taconics/GenPharm	NULL
International	NULL
(	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

All	NULL
animals	NULL
were	NULL
bred	NULL
and	NULL
maintained	NULL
in	NULL
a	NULL
pathogen-free	NULL
environment	NULL
at	NULL
Jefferson	NULL
Medical	NULL
College	NULL
,	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
.	NULL

All	NULL
animal	NULL
protocols	NULL
were	NULL
approved	NULL
by	NULL
the	NULL
Institutional	NULL
Animal	NULL
Care	NULL
and	NULL
Use	NULL
Committee	NULL
,	NULL
and	NULL
NIH	NULL
guidelines	NULL
for	NULL
animal	NULL
care	NULL
were	NULL
followed	NULL
throughout	NULL
.	NULL

The	NULL
construct	NULL
LCK-TAL-1	NULL
was	NULL
generated	NULL
by	NULL
insertion	NULL
of	NULL
a	NULL
1.2-kb	NULL
fragment	NULL
containing	NULL
the	NULL
coding	NULL
region	NULL
and	NULL
a	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
human	NULL
TAL-/	NULL
cDNA	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
TAL-1	NULL
cDNA	NULL
was	NULL
rendered	NULL
BamHI-compatible	NULL
on	NULL
both	NULL
ends	NULL
and	NULL
inserted	NULL
into	NULL
the	NULL
unique	NULL
BamHI	NULL
cloning	NULL
site	NULL
downstream	NULL
to	NULL
the	NULL
LCK	NULL
promoter	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
3	NULL
'	NULL
untranslated	NULL
portion	NULL
of	NULL
this	NULL
construct	NULL
encompasses	NULL
introns	NULL
,	NULL
exons	NULL
,	NULL
and	NULL
polyA	NULL
addition	NULL
sites	NULL
from	NULL
the	NULL
human	NULL
growth	NULL
hormone	NULL
gene	NULL
.	NULL

The	NULL
6.8-kb	NULL
LCK-TAL-1	NULL
fragment	NULL
digested	NULL
by	NULL
SaclIl	NULL
was	NULL
used	NULL
for	NULL
microinjec-tion	NULL
.	NULL

Transgenic	NULL
animals	NULL
were	NULL
generated	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Transgenic	NULL
progeny	NULL
were	NULL
identified	NULL
by	NULL
Southern	NULL
blotting	NULL
of	NULL
Sacl-digested	NULL
tail	NULL
DNA	NULL
using	NULL
the	NULL
entire	NULL
LCK-TAL-1	NULL
fragment	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

RT-PCR	NULL
mRNA	NULL
Analysis	NULL
Methodology	NULL
for	NULL
semiquantitative	NULL
RT-PCR	NULL
analysis	NULL
has	NULL
been	NULL
reported	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
total	NULL
RNA	NULL
extracted	NULL
by	NULL
the	NULL
guanidinium	NULL
isothiocya-	NULL
5113	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

T	NULL
LYMPHOMAS	NULL
IN	NULL
TRANSGENIC	NULL
tal-1	NULL
MICE	NULL
tal-1-cDNA	NULL
Ecmoxma	NULL
Fromm	NULL
Sac	NULL
II	NULL
Bam	NULL
HI	NULL
Sac	NULL
II	NULL
I	NULL
--	NULL
500	NULL
bp	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

LCK-TAL-1	NULL
transgene	NULL
construct	NULL
.	NULL

A	NULL
1.2-kb	NULL
cDNA	NULL
(	NULL
closed	NULL
arrow	NULL
)	NULL
to	NULL
human	NULL
TAL-1	NULL
was	NULL
inserted	NULL
at	NULL
the	NULL
BamHI	NULL
site	NULL
downstream	NULL
to	NULL
the	NULL
3.2-kb	NULL
LCK	NULL
proximal	NULL
promoter	NULL
(	NULL
open	NULL
box	NULL
)	NULL
.	NULL

Introns	NULL
,	NULL
exons	NULL
,	NULL
and	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
addition	NULL
sites	NULL
(	NULL
Ratched	NULL
boxes	NULL
)	NULL
of	NULL
human	NULL
growth	NULL
hormone	NULL
constitute	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
.	NULL

A	NULL
wt	NULL
Lok-tai-1	NULL
Control	NULL
ge	NULL
Si	NULL
conman	NULL
|	NULL
1	NULL
20	NULL
3	NULL
4	NULL
5	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
g	NULL
Â§	NULL
ma	NULL
a-~	NULL
>	NULL
>	NULL
can	NULL
-	NULL
OÂ®O-~~+	NULL
B	NULL
spleen	NULL
thymus	NULL
wt	NULL
Lek-takl	NULL
wt	NULL
Lek-tai-1	NULL
42	NULL
Kc	NULL
-	NULL
tie	NULL
>	NULL
s	NULL
as	NULL
@	NULL
#	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
,	NULL
semiquantitative	NULL
RT-PCR	NULL
of	NULL
tal-1	NULL
mRNA	NULL
from	NULL
spleen	NULL
(	NULL
Lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
)	NULL
and	NULL
thymus	NULL
(	NULL
Lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
of	NULL
nontransgenic	NULL
(	NULL
wt	NULL
,	NULL
wild	NULL
type	NULL
;	NULL
Lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
and	NULL
transgenic	NULL
Lok-tal-	NULL
]	NULL
(	NULL
Lanes	NULL
5-10	NULL
)	NULL
mice	NULL
(	NULL
top	NULL
)	NULL
.	NULL

Three	NULL
Lok-tal-1	NULL
transgenic	NULL
lines	NULL
were	NULL
evaluated	NULL
:	NULL
line	NULL
1849	NULL
,	NULL
Lanes	NULL
5	NULL
and	NULL
6	NULL
;	NULL
line	NULL
1856	NULL
,	NULL
Lanes	NULL
7	NULL
and	NULL
8	NULL
;	NULL
and	NULL
line	NULL
1859	NULL
,	NULL
Lanes	NULL
9	NULL
and	NULL
10	NULL
.	NULL

GAPDH	NULL
gene	NULL
was	NULL
used	NULL
for	NULL
normalization	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

The	NULL
controls	NULL
for	NULL
semiquantitative	NULL
RT-PCR	NULL
analysis	NULL
are	NULL
detailed	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
K562	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
was	NULL
the	NULL
internal	NULL
positive	NULL
control	NULL
.	NULL

Representative	NULL
results	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
TAL-1	NULL
filter	NULL
was	NULL
autoradiographed	NULL
for	NULL
10	NULL
h	NULL
,	NULL
and	NULL
the	NULL
GAPDH	NULL
filter	NULL
was	NULL
autoradiographed	NULL
for	NULL
3	NULL
h.	NULL
B	NULL
,	NULL
tal-1	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
proteins	NULL
from	NULL
spleen	NULL
(	NULL
Lanes	NULL
1-4	NULL
)	NULL
and	NULL
thymus	NULL
(	NULL
Lanes	NULL
5-8	NULL
)	NULL
of	NULL
nontransgenic	NULL
mice	NULL
(	NULL
Lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
transgenic	NULL
lines	NULL
1849	NULL
(	NULL
Lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
and	NULL
1856	NULL
(	NULL
Lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
equivalent	NULL
amount	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
of	NULL
total	NULL
cell	NULL
extract	NULL
from	NULL
spleen	NULL
and	NULL
thymus	NULL
of	NULL
transgenic	NULL
and	NULL
nontransgenic	NULL
mice	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
was	NULL
used	NULL
as	NULL
positive	NULL
control	NULL
.	NULL

The	NULL
molecular	NULL
weight	NULL
marker	NULL
is	NULL
indicated	NULL
in	NULL
thousands	NULL
(	NULL
kd	NULL
)	NULL
.	NULL

Representative	NULL
results	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

Filters	NULL
were	NULL
developed	NULL
by	NULL
ECL	NULL
detection	NULL
and	NULL
exposed	NULL
to	NULL
X-ray	NULL
film	NULL
for	NULL
20	NULL
min	NULL
(	NULL
spleen	NULL
,	NULL
Lanes	NULL
/-4	NULL
)	NULL
and	NULL
2	NULL
min	NULL
(	NULL
thymus	NULL
,	NULL
Lanes	NULL
5-8	NULL
)	NULL
.	NULL

nate-CsCl	NULL
method	NULL
from	NULL
the	NULL
same	NULL
number	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
12	NULL
ug	NULL
of	NULL
Escherichia	NULL
coli	NULL
tRNA	NULL
was	NULL
quantitated	NULL
by	NULL
dot	NULL
hybridization	NULL
with	NULL
a	NULL
human	NULL
rRNA	NULL
probe	NULL
.	NULL

After	NULL
densitometric	NULL
analysis	NULL
,	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
RNA	NULL
(	NULL
~200	NULL
ng	NULL
)	NULL
was	NULL
reverse-transcribed	NULL
(	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
RT	NULL
;	NULL
Life	NULL
Tech-nologies	NULL
,	NULL
Inc.	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
with	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
as	NULL
primer	NULL
.	NULL

cDNAs	NULL
were	NULL
normalized	NULL
by	NULL
the	NULL
GAPDH	NULL
gene	NULL
using	NULL
the	NULL
following	NULL
primers	NULL
:	NULL
5	NULL
'	NULL
primer	NULL
,	NULL
5'-ACATCAAGAAGGTGGTGAAGCAGG-3	NULL
'	NULL
;	NULL
and	NULL
3	NULL
'	NULL
primer	NULL
,	NULL
CTCTTGTGCTCTTGCTGG-3	NULL
'	NULL
(	NULL
probe	NULL
,	NULL
880	NULL
to	NULL
914	NULL
bp	NULL
)	NULL
.	NULL

Amplification	NULL
of	NULL
~5	NULL
ng	NULL
of	NULL
RT-RNA	NULL
within	NULL
the	NULL
linear	NULL
range	NULL
was	NULL
achieved	NULL
by	NULL
20	NULL
PCR	NULL
cycles	NULL
(	NULL
denaturation	NULL
at	NULL
95Â°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
annealing	NULL
at	NULL
56Â°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
72Â°C	NULL
for	NULL
45	NULL
s	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
expression	NULL
of	NULL
an	NULL
aliquot	NULL
of	NULL
RT-RNA	NULL
(	NULL
~20	NULL
ng	NULL
)	NULL
was	NULL
amplified	NULL
within	NULL
the	NULL
linear	NULL
range	NULL
by	NULL
40	NULL
PCR	NULL
cycles	NULL
(	NULL
ie	NULL
.	NULL

,	NULL
the	NULL
cycle	NULL
number	NULL
allowed	NULL
a	NULL
linear	NULL
cDNA	NULL
dose	NULL
response	NULL
)	NULL
.	NULL

Each	NULL
sample	NULL
was	NULL
electrophoresed	NULL
in	NULL
a	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
filter	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
an	NULL
internal	NULL
oligomer	NULL
as	NULL
probe	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
RNA	NULL
(	NULL
~20	NULL
ng	NULL
)	NULL
of	NULL
each	NULL
sample	NULL
and	NULL
a	NULL
mock	NULL
reaction	NULL
(	NULL
negative	NULL
controls	NULL
)	NULL
were	NULL
amplified	NULL
to	NULL
exclude	NULL
the	NULL
presence	NULL
of	NULL
contaminant	NULL
DNA	NULL
.	NULL

The	NULL
following	NULL
5	NULL
'	NULL
,	NULL
3	NULL
'	NULL
primers	NULL
and	NULL
probe	NULL
were	NULL
used	NULL
for	NULL
5	NULL
'	NULL
primer	NULL
,	NULL
5'-ATGGTGCAGCTGAGTCCTCC-3	NULL
'	NULL
;	NULL
3	NULL
'	NULL
primer	NULL
,	NULL
5'-TCTCATTCTTGCT-GAGCTTC-3	NULL
'	NULL
;	NULL
and	NULL
probe	NULL
,	NULL
5-GATGCCTTCCCTATGTTCACCACCAA-CAAT-3	NULL
'	NULL
.	NULL

The	NULL
amplification	NULL
procedure	NULL
included	NULL
denaturation	NULL
at	NULL
95Â°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
annealing	NULL
at	NULL
54Â°C	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
72Â°C	NULL
for	NULL
45	NULL
s	NULL
during	NULL
40	NULL
PCR	NULL
cycles	NULL
,	NULL
ie	NULL
.	NULL

,	NULL
within	NULL
the	NULL
range	NULL
of	NULL
linear	NULL
amplification	NULL
.	NULL

RT-RNA	NULL
from	NULL
the	NULL
K562	NULL
cell	NULL
line	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
positive	NULL
control	NULL
in	NULL
each	NULL
PCR	NULL
.	NULL

Nuclear	NULL
and	NULL
Total	NULL
Cell	NULL
Extracts	NULL
Preparation	NULL
Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
were	NULL
obtained	NULL
as	NULL
described	NULL
by	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
.	NULL

For	NULL
EMSA	NULL
,	NULL
total	NULL
cell	NULL
extracts	NULL
from	NULL
spleen	NULL
and	NULL
thymus	NULL
of	NULL
adult	NULL
mice	NULL
were	NULL
prepared	NULL
from	NULL
single-cell	NULL
suspensions	NULL
lysed	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.4	NULL
m	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
2.5	NULL
mm	NULL
DTT	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mm	NULL
phenylmethyisulfony	NULL
]	NULL
fluoride	NULL
,	NULL
and	NULL
1	NULL
pg/ml	NULL
each	NULL
of	NULL
leupeptin	NULL
and	NULL
aprotinin	NULL
.	NULL

Cells	NULL
were	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
,	NULL
frozen	NULL
at	NULL
-70Â°C	NULL
,	NULL
and	NULL
thawed	NULL
once	NULL
.	NULL

The	NULL
suspension	NULL
was	NULL
vigorously	NULL
mixed	NULL
and	NULL
centrifuged	NULL
for	NULL
10	NULL
min	NULL
at	NULL
13,600	NULL
x	NULL
g	NULL
in	NULL
a	NULL
microcentrifuge	NULL
.	NULL

For	NULL
Western	NULL
blot	NULL
protein	NULL
assay	NULL
,	NULL
single-cell	NULL
suspensions	NULL
of	NULL
spleen	NULL
and	NULL
6	NULL
%	NULL
3	NULL
I	NULL
$	NULL
2	NULL
$	NULL
33	NULL
I1	NULL
21	NULL
31	NULL
Cems	NULL
tal-	NULL
1/E2A	NULL
--	NULL
B	NULL
Lane	NULL
No	NULL
.	NULL

1	NULL
200	NULL
3	NULL
4	NULL
5	NULL
Pre-immune	NULL
serum	NULL
<	NULL
00	NULL
Â«	NULL
0	NULL
os	NULL
=e	NULL
anti-E2A	NULL
serum	NULL
oe	NULL
anti-tal-1	NULL
serum	NULL
w	NULL
&	NULL
<	NULL
gp	NULL
o-tal-1/E2A	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
,	NULL
EMSA	NULL
of	NULL
TAL-1/E2A	NULL
complexes	NULL
in	NULL
total	NULL
cell	NULL
extract	NULL
of	NULL
spleen	NULL
(	NULL
8	NULL
,	NULL
Lanes	NULL
18-38	NULL
)	NULL
and	NULL
thymus	NULL
(	NULL
T	NULL
,	NULL
Lanes	NULL
1T-3T	NULL
)	NULL
of	NULL
nontransgenic	NULL
(	NULL
Lanes	NULL
18	NULL
and	NULL
1T	NULL
)	NULL
and	NULL
transgenic	NULL
lines	NULL
1849	NULL
(	NULL
Lanes	NULL
25	NULL
and	NULL
27	NULL
)	NULL
and	NULL
1856	NULL
(	NULL
Lanes	NULL
38	NULL
and	NULL
3T	NULL
)	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
canonical	NULL
tal-1/E2A	NULL
heterodimer	NULL
is	NULL
marked	NULL
;	NULL
tal-	NULL
1/E	NULL
protein	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
asterisks	NULL
.	NULL

B	NULL
,	NULL
EMSA	NULL
of	NULL
tal-	NULL
1/E2A	NULL
heterodimers	NULL
(	NULL
asterisks	NULL
)	NULL
in	NULL
thymus	NULL
total	NULL
cell	NULL
extract	NULL
of	NULL
nontransgenic	NULL
mice	NULL
line	NULL
1849	NULL
(	NULL
Lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
)	NULL
;	NULL
nontransgenic	NULL
mice	NULL
extract	NULL
is	NULL
shown	NULL
in	NULL
Lane	NULL
2	NULL
,	NULL
whereas	NULL
Jurkat	NULL
leukemic	NULL
T	NULL
cell	NULL
extracts	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
control	NULL
for	NULL
the	NULL
canonical	NULL
tal-1/E2A	NULL
heterodimer	NULL
(	NULL
Lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
complexes	NULL
in	NULL
transgenic	NULL
thymocytes	NULL
were	NULL
supershifted	NULL
(	NULL
arrow	NULL
)	NULL
by	NULL
incubation	NULL
with	NULL
anti-tal-1	NULL
serum	NULL
and	NULL
partially	NULL
abrogated	NULL
with	NULL
anti-E2A	NULL
serum	NULL
(	NULL
Lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
the	NULL
corresponding	NULL
preimmune	NULL
serum	NULL
(	NULL
Lane	NULL
3	NULL
)	NULL
.	NULL

5114	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

T	NULL
LYMPHOMAS	NULL
IN	NULL
TRANSGENIC	NULL
tal-1	NULL
MICE	NULL
Table	NULL
1	NULL
Membrane	NULL
antigen	NULL
phenotype	NULL
of	NULL
thymus	NULL
and	NULL
spleen	NULL
cells	NULL
from	NULL
wild-type	NULL
and	NULL
Lck-Tal-1	NULL
transgenic	NULL
mice	NULL
(	NULL
lines	NULL
1849	NULL
and	NULL
1856	NULL
)	NULL
Organ	NULL
Strain/Line	NULL
Cell	NULL
no	NULL
.	NULL

x	NULL
10Â°	NULL
CD3*	NULL
(	NULL
%	NULL
)	NULL
CD4*	NULL
CDS*	NULL
(	NULL
%	NULL
)	NULL
CD4*	NULL
(	NULL
%	NULL
)	NULL
CD8	NULL
*	NULL
(	NULL
%	NULL
)	NULL
CDASR*	NULL
(	NULL
%	NULL
)	NULL
Thymus	NULL
C57	NULL
black	NULL
22.3	NULL
*	NULL
3.6	NULL
``	NULL
25.0	NULL
+	NULL
3.2	NULL
92.8	NULL
+	NULL
1.1	NULL
96.75	NULL
*	NULL
1.03	NULL
96.0	NULL
+	NULL
0.40	NULL
ND	NULL
1849	NULL
20.0	NULL
*	NULL
3.1	NULL
34.3	NULL
+	NULL
4.2	NULL
87.5	NULL
#	NULL
1.4	NULL
97.0	NULL
+	NULL
2.0	NULL
96.0	NULL
+	NULL
1.0	NULL
ND	NULL
1856	NULL
31.7	NULL
+	NULL
4.0	NULL
26.5	NULL
+	NULL
2.8	NULL
83.4	NULL
+	NULL
3.4	NULL
92.83	NULL
+	NULL
2.27	NULL
87.0	NULL
+	NULL
8.05	NULL
ND	NULL
Spleen	NULL
C57	NULL
black	NULL
68.8	NULL
+	NULL
13.7	NULL
22.1	NULL
*+	NULL
2.0	NULL
ND	NULL
154	NULL
*	NULL
1.3	NULL
12.6	NULL
*	NULL
1.4	NULL
50.3	NULL
*	NULL
4.0	NULL
1849	NULL
58.0	NULL
*	NULL
14.4	NULL
32.0	NULL
*	NULL
1.8	NULL
``	NULL
ND	NULL
17.6	NULL
*	NULL
1.3	NULL
14.8	NULL
+	NULL
1.2	NULL
37.6	NULL
+	NULL
2.9	NULL
1856	NULL
55.8	NULL
*	NULL
11.3	NULL
39.1	NULL
+	NULL
20Â°	NULL
ND	NULL
22.9	NULL
+10	NULL
17.7	NULL
*	NULL
1.2	NULL
41.3	NULL
+	NULL
3.1	NULL
``	NULL
Mean	NULL
*	NULL
SE	NULL
values	NULL
.	NULL

Â®	NULL
p	NULL
<	NULL
0.05	NULL
when	NULL
compared	NULL
with	NULL
control	NULL
values	NULL
by	NULL
ANOVA	NULL
.	NULL

P	NULL
<	NULL
0.01	NULL
when	NULL
compared	NULL
with	NULL
control	NULL
values	NULL
by	NULL
ANOVA	NULL
.	NULL

Table	NULL
2	NULL
Proliferation	NULL
of	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
from	NULL
thymus	NULL
and	NULL
spleen	NULL
of	NULL
control	NULL
and	NULL
Lck-tal-1	NULL
transgenic	NULL
mice	NULL
after	NULL
ConA	NULL
or	NULL
IL-2	NULL
and	NULL
LPS	NULL
stimulus	NULL
.	NULL

respectively	NULL
C	NULL
H	NULL
)	NULL
-thymidine	NULL
incorporation	NULL
(	NULL
mean	NULL
+	NULL
SEM	NULL
``	NULL
)	NULL
Organ	NULL
Strain/Line	NULL
ConA	NULL
IL-2	NULL
LPS	NULL
Thymus	NULL
C57	NULL
Black	NULL
1.80	NULL
+	NULL
0.54	NULL
1.31	NULL
+	NULL
0.22	NULL
ND	NULL
1849	NULL
1.77	NULL
+	NULL
0.89	NULL
1.13	NULL
+	NULL
0.21	NULL
ND	NULL
1856	NULL
1.14	NULL
*	NULL
0.04	NULL
1.04	NULL
*+	NULL
0.07	NULL
ND	NULL
Spleen	NULL
C57	NULL
Black	NULL
254.8	NULL
+	NULL
52.0	NULL
4.28	NULL
*	NULL
0.34	NULL
35.89	NULL
+	NULL
9.61	NULL
1849	NULL
76.8	NULL
+	NULL
22.3	NULL
``	NULL
2.2	NULL
*	NULL
0.57	NULL
``	NULL
16.43	NULL
+	NULL
5.29	NULL
1856	NULL
91.7	NULL
+	NULL
24.1	NULL
``	NULL
1.26	NULL
+	NULL
0.07Â°	NULL
22.88	NULL
+	NULL
5.39	NULL
Peak	NULL
cpm	NULL
``	NULL
Stimulation	NULL
index	NULL
.	NULL

=	NULL
--	NULL
--	NULL
--	NULL
--	NULL
.	NULL

Control	NULL
peak	NULL
cpm	NULL
Â®	NULL
p	NULL
<	NULL
0.05	NULL
when	NULL
compared	NULL
to	NULL
control	NULL
values	NULL
by	NULL
ANOVA	NULL
.	NULL

``	NULL
P	NULL
<	NULL
0.01	NULL
when	NULL
compared	NULL
to	NULL
control	NULL
values	NULL
by	NULL
ANOVA	NULL
.	NULL

thymus	NULL
of	NULL
adult	NULL
mice	NULL
were	NULL
lysed	NULL
in	NULL
low	NULL
stringency	NULL
buffer	NULL
[	NULL
50	NULL
mm	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
0.5	NULL
%	NULL
NP4O	NULL
,	NULL
1	NULL
mm	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
0.02	NULL
%	NULL
sodium	NULL
azide	NULL
,	NULL
and	NULL
1	NULL
ug/ml	NULL
each	NULL
of	NULL
leupeptin	NULL
and	NULL
aprotinin	NULL
]	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
treated	NULL
as	NULL
described	NULL
above	NULL
for	NULL
EMSA	NULL
analysis	NULL
.	NULL

Western	NULL
Blot	NULL
and	NULL
EMSA	NULL
.	NULL

The	NULL
protein	NULL
concentrations	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Hertfordshire	NULL
,	NULL
United	NULL
King-dom	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
Tal-1	NULL
rabbit	NULL
antiserum	NULL
1080	NULL
as	NULL
described	NULL
by	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
as	NULL
reported	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Each	NULL
reaction	NULL
contained	NULL
,	NULL
in	NULL
20	NULL
pl	NULL
,	NULL
10	NULL
to	NULL
25	NULL
pug	NULL
of	NULL
cell	NULL
extract	NULL
,	NULL
10	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
50	NULL
mm	NULL
KCI	NULL
,	NULL
2	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
4	NULL
%	NULL
Ficoll	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
DTT	NULL
,	NULL
0.5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
di-dC	NULL
)	NULL
,	NULL
and	NULL
1	NULL
to	NULL
3	NULL
pmol	NULL
of	NULL
P-labeled	NULL
,	NULL
double-stranded	NULL
oligonucleotide	NULL
probe	NULL
containing	NULL
the	NULL
preferred	NULL
sequence	NULL
for	NULL
DNA	NULL
binding	NULL
by	NULL
TAL1/E2A	NULL
heterodimers	NULL
(	NULL
top	NULL
strand	NULL
,	NULL
ACCTGAACAGATGGTCG-GCT	NULL
;	NULL
Ref	NULL
.	NULL

21	NULL
)	NULL
.	NULL

After	NULL
a	NULL
15-min	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
assay	NULL
mixture	NULL
was	NULL
loaded	NULL
onto	NULL
a	NULL
15-cm	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
containing	NULL
0.25	NULL
X	NULL
TRIS-borate/EDTA	NULL
electrophoresis	NULL
buffer	NULL
and	NULL
electrophoresed	NULL
at	NULL
180	NULL
V	NULL
for	NULL
2-3	NULL
h	NULL
at	NULL
4Â°C	NULL
.	NULL

In	NULL
some	NULL
binding	NULL
reactions	NULL
,	NULL
the	NULL
extract	NULL
was	NULL
preincubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
1	NULL
ul	NULL
of	NULL
TAL-1	NULL
rabbit	NULL
antiserum	NULL
370	NULL
,	NULL
the	NULL
E2A	NULL
antiserum	NULL
526	NULL
,	NULL
or	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
normal	NULL
rabbit	NULL
immunoglobulin	NULL
(	NULL
20	NULL
)	NULL
.	NULL

FACS	NULL
and	NULL
Cell	NULL
Proliferation	NULL
Analyses	NULL
Cell	NULL
Preparation	NULL
and	NULL
Culture	NULL
.	NULL

Thymuses	NULL
and	NULL
spleens	NULL
from	NULL
8-	NULL
to	NULL
12-week-old	NULL
animals	NULL
were	NULL
minced	NULL
to	NULL
generate	NULL
a	NULL
single-cell	NULL
suspension	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

The	NULL
cell	NULL
suspension	NULL
was	NULL
filtered	NULL
through	NULL
nylon	NULL
mesh	NULL
and	NULL
scored	NULL
for	NULL
viable	NULL
cells	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
.	NULL

Viable	NULL
cells	NULL
were	NULL
always	NULL
>	NULL
90	NULL
%	NULL
.	NULL

Thymic	NULL
cell	NULL
``	NULL
starvation	NULL
``	NULL
culture	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
RPMI	NULL
1640	NULL
and	NULL
5	NULL
%	NULL
FCS	NULL
;	NULL
viable	NULL
cells	NULL
were	NULL
scored	NULL
as	NULL
indicated	NULL
above	NULL
.	NULL

Monoclonal	NULL
Antibodies	NULL
.	NULL

Phycoerythrin-	NULL
or	NULL
FITC-labeled	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
murine	NULL
CD4	NULL
,	NULL
CD8	NULL
,	NULL
CD3	NULL
,	NULL
and	NULL
CD4SR	NULL
were	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Fluorescence-activated	NULL
Cytometry	NULL
Analysis	NULL
.	NULL

Freshly	NULL
isolated	NULL
cells	NULL
from	NULL
thymuses	NULL
and	NULL
spleens	NULL
were	NULL
stained	NULL
for	NULL
two-	NULL
or	NULL
three-color	NULL
analysis	NULL
,	NULL
and	NULL
fluorescence	NULL
was	NULL
analyzed	NULL
using	NULL
a	NULL
dual	NULL
laser	NULL
FACS	NULL
IV	NULL
(	NULL
Becton-Dickinson	NULL
)	NULL
.	NULL

Dead	NULL
cells	NULL
were	NULL
detected	NULL
by	NULL
adding	NULL
1	NULL
pg/ml	NULL
!	NULL

propidium	NULL
iodide	NULL
and	NULL
gated	NULL
out	NULL
electronically	NULL
.	NULL

[	NULL
Â°H	NULL
]	NULL
Thymidine	NULL
Incorporation	NULL
Assay	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10Â°	NULL
per	NULL
ml	NULL
in	NULL
96-well	NULL
tissue	NULL
culture	NULL
plates	NULL
in	NULL
RPMI	NULL
1640	NULL
and	NULL
10	NULL
%	NULL
FCS	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
ConA	NULL
(	NULL
0.5	NULL
,	NULL
1	NULL
,	NULL
2.5	NULL
,	NULL
and	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
murine	NULL
recombinant	NULL
interleukin	NULL
2	NULL
(	NULL
10	NULL
and	NULL
100	NULL
units/ml	NULL
)	NULL
,	NULL
or	NULL
bacterial	NULL
LPS	NULL
(	NULL
0.5	NULL
,	NULL
5	NULL
,	NULL
20	NULL
,	NULL
and	NULL
40	NULL
ug/ml	NULL
)	NULL
.	NULL

After	NULL
a	NULL
72-h	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
pulsed	NULL
for	NULL
8	NULL
additional	NULL
hours	NULL
with	NULL
1	NULL
Ci	NULL
[	NULL
*HJthymidine/well	NULL
,	NULL
collected	NULL
,	NULL
and	NULL
scintillation	NULL
counted	NULL
.	NULL

ConA	NULL
and	NULL
LPS	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
and	NULL
IL-2	NULL
from	NULL
Genzyme	NULL
Corp.	NULL
(	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Histological	NULL
and	NULL
Immunohistochemical	NULL
Analyses	NULL
Histological	NULL
and	NULL
histochemical	NULL
analyses	NULL
were	NULL
performed	NULL
on	NULL
lymphoid	NULL
tissues	NULL
fixed	NULL
in	NULL
10	NULL
%	NULL
buffered	NULL
formalin	NULL
and	NULL
processed	NULL
for	NULL
paraffin	NULL
embedding	NULL
by	NULL
Pathology	NULL
Associates	NULL
International	NULL
(	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Serial	NULL
sections	NULL
were	NULL
stained	NULL
with	NULL
H	NULL
&	NULL
E	NULL
using	NULL
standard	NULL
procedures	NULL
.	NULL

Immunohistochemical	NULL
analyses	NULL
were	NULL
performed	NULL
on	NULL
fixed	NULL
tissues	NULL
as	NULL
described	NULL
by	NULL
Bind	NULL
]	NULL
et	NULL
al	NULL
.	NULL

(	NULL
28	NULL
)	NULL
.	NULL

Immunoper-oxidase-conjugated	NULL
antimouse	NULL
CD3	NULL
and	NULL
CD45R	NULL
mouse	NULL
monoclonal	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
PharMingen	NULL
.	NULL

Results	NULL
Transgenic	NULL
Mice	NULL
.	NULL

We	NULL
developed	NULL
a	NULL
transgenic	NULL
mouse	NULL
model	NULL
to	NULL
assess	NULL
the	NULL
effects	NULL
of	NULL
tal-1	NULL
expression	NULL
in	NULL
lymphoid	NULL
tissues	NULL
.	NULL

A	NULL
transgenic	NULL
construct	NULL
was	NULL
generated	NULL
by	NULL
inserting	NULL
a	NULL
human	NULL
TAL-/	NULL
cDNA	NULL
downstream	NULL
of	NULL
the	NULL
LCK	NULL
promoter	NULL
(	NULL
Refs	NULL
.	NULL

26	NULL
and	NULL
29	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Seven	NULL
founders	NULL
bearing	NULL
LCK-TAL-1	NULL
were	NULL
identified	NULL
by	NULL
Southern	NULL
blot	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
corresponding	NULL
lines	NULL
were	NULL
established	NULL
.	NULL

Each	NULL
line	NULL
was	NULL
examined	NULL
by	NULL
Western	NULL
blot	NULL
(	NULL
see	NULL
below	NULL
)	NULL
and	NULL
RT-PCR	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Three	NULL
lines	NULL
(	NULL
1849	NULL
,	NULL
1856	NULL
,	NULL
and	NULL
1859	NULL
)	NULL
were	NULL
further	NULL
character-ized	NULL
,	NULL
two	NULL
of	NULL
which	NULL
were	NULL
extensively	NULL
studied	NULL
(	NULL
1849	NULL
and	NULL
1856	NULL
)	NULL
.	NULL

TAL-1	NULL
mRNA	NULL
was	NULL
present	NULL
in	NULL
the	NULL
spleen	NULL
and	NULL
thymus	NULL
of	NULL
transgenic	NULL
mice	NULL
but	NULL
not	NULL
in	NULL
wild-type	NULL
animals	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
RT-PCR	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Transgenic	NULL
mice	NULL
express	NULL
a	NULL
42-kDa	NULL
tal-1	NULL
100	NULL
80	NULL
%	NULL
of	NULL
survival	NULL
S	NULL
20	NULL
C-T-O-T-	NULL
TO	NULL
'	NULL
]	NULL
0	NULL
Weeks	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Survival	NULL
curve	NULL
of	NULL
transgenic	NULL
and	NULL
control	NULL
mice	NULL
:	NULL
CJ	NULL
,	NULL
wild-type	NULL
mice	NULL
;	NULL
O	NULL
,	NULL
transgenic	NULL
mice	NULL
line	NULL
1849	NULL
;	NULL
MB	NULL
,	NULL
line	NULL
1856	NULL
.	NULL

Table	NULL
3	NULL
Histopathology	NULL
analysis	NULL
of	NULL
tal-1	NULL
transgenic	NULL
mice	NULL
Transgenic	NULL
line	NULL
1849	NULL
1856	NULL
Number	NULL
of	NULL
mice	NULL
analyzed	NULL
18	NULL
11	NULL
Incidence	NULL
of	NULL
lymphoid	NULL
hyperplasia	NULL
33.3	NULL
%	NULL
30	NULL
%	NULL
Incidence	NULL
of	NULL
lymphomas	NULL
66.7	NULL
%	NULL
60	NULL
%	NULL
Cell	NULL
type	NULL
of	NULL
lymphomas	NULL
T	NULL
(	NULL
+	NULL
minor	NULL
B	NULL
component	NULL
T	NULL
(	NULL
+	NULL
minor	NULL
B	NULL
component	NULL
in	NULL
80	NULL
%	NULL
of	NULL
tumors	NULL
)	NULL
in	NULL
80	NULL
%	NULL
of	NULL
tumors	NULL
)	NULL
5115	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

T	NULL
LYMPHOMAS	NULL
IN	NULL
TRANSGENIC	NULL
tal-1	NULL
MICE	NULL
%	NULL
Â®	NULL
%	NULL
%	NULL
@	NULL
L	NULL
Â»	NULL
#	NULL
,	NULL
C	NULL
â¬	NULL
#	NULL
%	NULL
*	NULL
;	NULL
Â£	NULL
l	NULL
3	NULL
Â®	NULL
-	NULL
-	NULL
&	NULL
Â»	NULL
&	NULL
%	NULL
#	NULL
ty	NULL
49	NULL
:	NULL
A	NULL
%	NULL
i	NULL
-	NULL
#	NULL
#	NULL
%	NULL
#	NULL
â	NULL
Â¢	NULL
Â®	NULL
.	NULL

``	NULL
e	NULL
a	NULL
U	NULL
â¬	NULL
#	NULL
Â¢	NULL
a	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Representative	NULL
lymphoblastic	NULL
lymphoma	NULL
in	NULL
transgenic	NULL
mice	NULL
(	NULL
strain	NULL
1849	NULL
)	NULL
.	NULL

A	NULL
,	NULL
H	NULL
&	NULL
E	NULL
staining	NULL
.	NULL

Immunohistochemical	NULL
staining	NULL
of	NULL
lymphoma	NULL
localized	NULL
in	NULL
the	NULL
liver	NULL
with	NULL
a	NULL
peroxidase	NULL
conjugated	NULL
anti-CD3	NULL
(	NULL
B-C	NULL
)	NULL
or	NULL
anti-CD45R	NULL
antibody	NULL
(	NULL
D	NULL
)	NULL
.	NULL

protein	NULL
in	NULL
the	NULL
thymus	NULL
and	NULL
spleen	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
;	NULL
the	NULL
expression	NULL
in	NULL
the	NULL
thymus	NULL
is	NULL
higher	NULL
than	NULL
in	NULL
the	NULL
spleen	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
difference	NULL
in	NULL
T-cell	NULL
number	NULL
in	NULL
these	NULL
organs	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
LCK	NULL
is	NULL
expressed	NULL
at	NULL
higher	NULL
level	NULL
in	NULL
immature	NULL
than	NULL
mature	NULL
T	NULL
cells	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Ectopic	NULL
tal-1	NULL
Forms	NULL
a	NULL
DNA	NULL
Binding	NULL
Complex	NULL
with	NULL
E2A	NULL
Protein	NULL
in	NULL
Lok-tal-1	NULL
Mice	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
that	NULL
tal-1	NULL
has	NULL
the	NULL
ability	NULL
to	NULL
bind	NULL
DNA	NULL
only	NULL
when	NULL
it	NULL
associates	NULL
with	NULL
E2A	NULL
protein	NULL
(	NULL
14	NULL
,	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
in	NULL
diverse	NULL
cell	NULL
lines	NULL
,	NULL
ectopic	NULL
expression	NULL
of	NULL
the	NULL
TAL-/	NULL
gene	NULL
product	NULL
exerts	NULL
both	NULL
proliferative	NULL
and	NULL
antidifferentiative	NULL
effects	NULL
,	NULL
which	NULL
depend	NULL
on	NULL
both	NULL
the	NULL
basic	NULL
and	NULL
HLH	NULL
domains	NULL
(	NULL
25	NULL
)	NULL
necessary	NULL
for	NULL
binding	NULL
to	NULL
DNA	NULL
and	NULL
E2A	NULL
protein	NULL
,	NULL
respectively	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
tal-1	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
was	NULL
able	NULL
to	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
E2A	NULL
protein	NULL
and	NULL
bind	NULL
efficiently	NULL
to	NULL
its	NULL
DNA	NULL
consensus	NULL
sequence	NULL
,	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
total	NULL
extracts	NULL
obtained	NULL
from	NULL
thymus	NULL
or	NULL
spleen	NULL
of	NULL
transgenic	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
the	NULL
spleen	NULL
,	NULL
a	NULL
band	NULL
closely	NULL
comigrates	NULL
with	NULL
the	NULL
canonical	NULL
tal-1/E2A	NULL
protein	NULL
complex	NULL
in	NULL
Jurkat	NULL
cells	NULL
;	NULL
in	NULL
thymus	NULL
,	NULL
this	NULL
band	NULL
was	NULL
more	NULL
clearly	NULL
visible	NULL
,	NULL
together	NULL
with	NULL
an	NULL
additional	NULL
faster	NULL
migrating	NULL
band	NULL
,	NULL
whereas	NULL
no	NULL
protein	NULL
complex	NULL
was	NULL
detectable	NULL
in	NULL
control	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
whether	NULL
the	NULL
components	NULL
of	NULL
this	NULL
complex	NULL
included	NULL
tal-1	NULL
and	NULL
E2A	NULL
proteins	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
with	NULL
anti-tal-1	NULL
(	NULL
spleen	NULL
and	NULL
thymus	NULL
)	NULL
or	NULL
anti-E2A	NULL
serum	NULL
(	NULL
thymus	NULL
)	NULL
,	NULL
and	NULL
EMSA	NULL
was	NULL
performed	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
and	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
the	NULL
bands	NULL
corresponding	NULL
to	NULL
the	NULL
tal-1/E2A	NULL
complex	NULL
were	NULL
either	NULL
decreased	NULL
or	NULL
supershifted	NULL
,	NULL
thus	NULL
showing	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
proteins	NULL
in	NULL
the	NULL
nuclear	NULL
complex	NULL
.	NULL

The	NULL
intensity	NULL
of	NULL
the	NULL
radioactive	NULL
bands	NULL
was	NULL
higher	NULL
in	NULL
the	NULL
thymus	NULL
than	NULL
in	NULL
the	NULL
spleen	NULL
,	NULL
thus	NULL
in	NULL
agreement	NULL
with	NULL
Western	NULL
blot	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
tal-1	NULL
Expression	NULL
on	NULL
T-Cell	NULL
Maturation	NULL
and	NULL
Function	NULL
.	NULL

FACS	NULL
analysis	NULL
was	NULL
performed	NULL
in	NULL
3-7-week-old	NULL
mice	NULL
to	NULL
investigate	NULL
whether	NULL
tal-1	NULL
expression	NULL
alters	NULL
T-	NULL
or	NULL
B-cell	NULL
development	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
percentage	NULL
of	NULL
CD3Â¢*	NULL
,	NULL
CD4*/8*	NULL
,	NULL
CD4*	NULL
,	NULL
CD8	NULL
*	NULL
,	NULL
and	NULL
CD45R	NULL
*	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
transgenic	NULL
thymus	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
bor-derline	NULL
,	NULL
nonsignificant	NULL
increase	NULL
or	NULL
decrease	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
CD3	NULL
*	NULL
or	NULL
CD4*/CD8	NULL
*	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
mice	NULL
.	NULL

In	NULL
the	NULL
transgenic	NULL
spleen	NULL
:	NULL
(	NULL
a	NULL
)	NULL
the	NULL
percentage	NULL
of	NULL
CD3	NULL
Â¢	NULL
and	NULL
CD4*	NULL
cells	NULL
was	NULL
increased	NULL
(	NULL
although	NULL
nonsignificantly	NULL
for	NULL
the	NULL
latter	NULL
parameter	NULL
in	NULL
the	NULL
1849	NULL
line	NULL
)	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
mice	NULL
;	NULL
and	NULL
(	NULL
b	NULL
)	NULL
the	NULL
number	NULL
of	NULL
CD8*	NULL
or	NULL
CD4SR*	NULL
cells	NULL
showed	NULL
a	NULL
borderline	NULL
but	NULL
not	NULL
significant	NULL
increase	NULL
or	NULL
decrease	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
morphological	NULL
profile	NULL
of	NULL
the	NULL
FACS	NULL
scatter	NULL
did	NULL
not	NULL
show	NULL
gross	NULL
abnormality	NULL
when	NULL
transgenic	NULL
animals	NULL
were	NULL
compared	NULL
with	NULL
controls	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
TAL-1	NULL
interferes	NULL
with	NULL
the	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
thymus	NULL
or	NULL
spleen	NULL
,	NULL
primary	NULL
cultures	NULL
of	NULL
these	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
appropriate	NULL
amounts	NULL
of	NULL
IL-2	NULL
and	NULL
ConA	NULL
,	NULL
and	NULL
mitotic	NULL
response	NULL
was	NULL
evaluated	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
[	NULL
Â°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

%	NULL
of	NULL
Thymocyte	NULL
survival	NULL
Days	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Low	NULL
FCS	NULL
starvation	NULL
culture	NULL
of	NULL
thymic	NULL
cells	NULL
from	NULL
wild-type	NULL
(	NULL
O	NULL
)	NULL
or	NULL
Lok-tal-	NULL
1	NULL
(	NULL
@	NULL
;	NULL
line	NULL
1849	NULL
)	NULL
mice	NULL
.	NULL

Mean	NULL
values	NULL
are	NULL
presented	NULL
;	NULL
bars	NULL
,	NULL
SE	NULL
.	NULL

5116	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

T	NULL
LYMPHOMAS	NULL
IN	NULL
TRANSGENIC	NULL
tal-	NULL
MICE	NULL
100	NULL
80	NULL
3	NULL
eo	NULL
2	NULL
6	NULL
s	NULL
40	NULL
ta	NULL
}	NULL
FS	NULL
20	NULL
0	NULL
[	NULL
OOC	NULL
OT	NULL
C	NULL
T	NULL
T	NULL
O	NULL
O	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
Weeks	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Survival	NULL
curves	NULL
of	NULL
mice	NULL
with	NULL
the	NULL
following	NULL
genotype	NULL
:	NULL
TAL-7~'*	NULL
(	NULL
O	NULL
)	NULL
;	NULL
p53	NULL
*	NULL
(	NULL
O	NULL
)	NULL
;	NULL
and	NULL
TAL-I~	NULL
*/p53~'*	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Table	NULL
4	NULL
Histopathology	NULL
analysis	NULL
of	NULL
p53	NULL
'*	NULL
Aal-1~'*	NULL
transgenic	NULL
mice	NULL
Transgenic	NULL
line	NULL
1849/p53	NULL
Number	NULL
of	NULL
mice	NULL
analyzed	NULL
22	NULL
Incidence	NULL
of	NULL
lymphoid	NULL
hyperplasia	NULL
Incidence	NULL
of	NULL
lymphomas	NULL
100	NULL
%	NULL
Cell	NULL
type	NULL
of	NULL
tymphomas	NULL
T	NULL
The	NULL
effects	NULL
of	NULL
these	NULL
stimuli	NULL
were	NULL
sharply	NULL
decreased	NULL
in	NULL
the	NULL
splenic	NULL
cells	NULL
of	NULL
transgenic	NULL
mice	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
animals	NULL
;	NULL
the	NULL
apparent	NULL
decrease	NULL
observed	NULL
for	NULL
thymic	NULL
cells	NULL
was	NULL
not	NULL
significant	NULL
.	NULL

Transgenic	NULL
B	NULL
cells	NULL
stimulated	NULL
by	NULL
LPS	NULL
showed	NULL
a	NULL
borderline	NULL
nonsignificant	NULL
decrease	NULL
of	NULL
incorporation	NULL
values	NULL
,	NULL
when	NULL
compared	NULL
with	NULL
controls	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Survival	NULL
of	NULL
Lok-tal-1	NULL
Mice	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
potential	NULL
oncogenic	NULL
effects	NULL
of	NULL
tal-1	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
grouped	NULL
30	NULL
animals	NULL
for	NULL
each	NULL
strain	NULL
(	NULL
1849	NULL
and	NULL
1856	NULL
)	NULL
into	NULL
two	NULL
cohorts	NULL
,	NULL
which	NULL
were	NULL
followed	NULL
for	NULL
70	NULL
weeks	NULL
,	NULL
together	NULL
with	NULL
a	NULL
cohort	NULL
of	NULL
control	NULL
,	NULL
age-matched	NULL
mice	NULL
derived	NULL
from	NULL
control	NULL
littermates	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
differences	NULL
in	NULL
survival	NULL
were	NULL
striking	NULL
;	NULL
most	NULL
of	NULL
the	NULL
transgenic	NULL
animals	NULL
died	NULL
by	NULL
the	NULL
end	NULL
of	NULL
the	NULL
observation	NULL
period	NULL
,	NULL
while	NULL
control	NULL
mice	NULL
were	NULL
alive	NULL
.	NULL

Histopathological	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
moribund	NULL
or	NULL
dead	NULL
mice	NULL
(	NULL
Table	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
lymphoid	NULL
hyperplasia	NULL
and/or	NULL
frank	NULL
lymphoma	NULL
was	NULL
evaluated	NULL
.	NULL

In	NULL
both	NULL
lines	NULL
,	NULL
the	NULL
number	NULL
of	NULL
lymphoid	NULL
tumors	NULL
was	NULL
high	NULL
and	NULL
were	NULL
combined	NULL
with	NULL
prevalent	NULL
lymphoid	NULL
hyper-plasia	NULL
.	NULL

Most	NULL
lymphoid	NULL
tumors	NULL
expressed	NULL
the	NULL
CD3	NULL
antigen	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
histochemical	NULL
analysis	NULL
;	NULL
the	NULL
type	NULL
of	NULL
tumors	NULL
varied	NULL
from	NULL
lym-phocytic	NULL
lymphoma	NULL
to	NULL
lymphoblastic	NULL
lymphoma	NULL
.	NULL

Particularly	NULL
,	NULL
80	NULL
%	NULL
of	NULL
tumors	NULL
expressed	NULL
a	NULL
mixed	NULL
T	NULL
and	NULL
B	NULL
phenotype	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
the	NULL
positivity	NULL
for	NULL
both	NULL
CD3	NULL
and	NULL
CD4SR	NULL
(	NULL
CD4SR	NULL
*	NULL
cells	NULL
ranged	NULL
from	NULL
<	NULL
5	NULL
to	NULL
50	NULL
%	NULL
in	NULL
some	NULL
tumors	NULL
)	NULL
.	NULL

Approximately	NULL
20	NULL
%	NULL
of	NULL
tumors	NULL
were	NULL
of	NULL
T	NULL
origin	NULL
only	NULL
.	NULL

Whether	NULL
B-cell	NULL
proliferation	NULL
is	NULL
determined	NULL
by	NULL
a	NULL
lack	NULL
of	NULL
T-cell	NULL
function	NULL
or	NULL
by	NULL
tal-1	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
has	NULL
not	NULL
been	NULL
established	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
a	NULL
potent	NULL
effect	NULL
of	NULL
tal-1	NULL
on	NULL
T-cell	NULL
tumorigenesis	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Interestingly	NULL
,	NULL
thymic	NULL
cells	NULL
from	NULL
transgenic	NULL
mice	NULL
,	NULL
cultured	NULL
in	NULL
low	NULL
FCS	NULL
concentration	NULL
without	NULL
exogenous	NULL
growth	NULL
factors	NULL
or	NULL
mitogens	NULL
,	NULL
showed	NULL
a	NULL
significantly	NULL
enhanced	NULL
survival	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
wild-type	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Standard	NULL
FACS	NULL
analysis	NULL
following	NULL
propidium	NULL
iodide	NULL
staining	NULL
showed	NULL
that	NULL
the	NULL
number	NULL
of	NULL
apoptotic	NULL
cells	NULL
was	NULL
consistently	NULL
lower	NULL
in	NULL
transgenic	NULL
than	NULL
wild-type	NULL
cell	NULL
cultures	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
p53	NULL
Heterozygosity	NULL
on	NULL
Survival	NULL
of	NULL
Lek-tal-1	NULL
Mice	NULL
.	NULL

Many	NULL
potential	NULL
oncogenes	NULL
fully	NULL
express	NULL
their	NULL
proliferative	NULL
potential	NULL
only	NULL
when	NULL
the	NULL
cell	NULL
cycle	NULL
checkpoints	NULL
are	NULL
altered	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

To	NULL
definitively	NULL
establish	NULL
whether	NULL
is	NULL
an	NULL
oncogene	NULL
,	NULL
it	NULL
was	NULL
necessary	NULL
to	NULL
show	NULL
that	NULL
TAL-I	NULL
increases	NULL
its	NULL
oncogenic	NULL
potential	NULL
in	NULL
these	NULL
altered	NULL
conditions	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
loss	NULL
of	NULL
a	NULL
p53	NULL
allele	NULL
.	NULL

Thus	NULL
,	NULL
p53~'~	NULL
male	NULL
mice	NULL
where	NULL
cross-bred	NULL
with	NULL
tal-1*'*	NULL
mice	NULL
from	NULL
strain	NULL
1849	NULL
.	NULL

A	NULL
number	NULL
of	NULL
F	NULL
,	NULL
mice	NULL
was	NULL
obtained	NULL
with	NULL
the	NULL
genotype	NULL
tal-1*'~/p53	NULL
.	NULL

A	NULL
cohort	NULL
of	NULL
30	NULL
animals	NULL
was	NULL
established	NULL
and	NULL
compared	NULL
with	NULL
two	NULL
other	NULL
cohorts	NULL
with	NULL
the	NULL
same	NULL
number	NULL
of	NULL
animals	NULL
bearing	NULL
the	NULL
genotype	NULL
p53	NULL
~	NULL
or	NULL
tal-1*'~	NULL
,	NULL
which	NULL
had	NULL
been	NULL
obtained	NULL
by	NULL
crossing	NULL
the	NULL
homozygous	NULL
tal-1	NULL
*'*	NULL
or	NULL
p53	NULL
~~	NULL
mice	NULL
with	NULL
wild-type	NULL
animals	NULL
.	NULL

The	NULL
mice	NULL
were	NULL
followed	NULL
for	NULL
approximately	NULL
70	NULL
weeks	NULL
;	NULL
most	NULL
of	NULL
tal-1	NULL
*'~/p53	NULL
*'~	NULL
animals	NULL
were	NULL
dead	NULL
by	NULL
that	NULL
age	NULL
,	NULL
thus	NULL
in	NULL
striking	NULL
contrast	NULL
with	NULL
the	NULL
other	NULL
two	NULL
cohorts	NULL
of	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Histopathological	NULL
analysis	NULL
,	NULL
conducted	NULL
on	NULL
22	NULL
tal-1	NULL
*'~/p53*'~	NULL
mice	NULL
,	NULL
showed	NULL
lymphomas	NULL
of	NULL
T	NULL
origin	NULL
in	NULL
all	NULL
cases	NULL
(	NULL
Table	NULL
4	NULL
;	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Discussion	NULL
Data	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
TAL-	NULL
]	NULL
is	NULL
highly	NULL
oncogenic	NULL
when	NULL
ectopically	NULL
expressed	NULL
in	NULL
lymphoid	NULL
cells	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
all	NULL
animals	NULL
died	NULL
of	NULL
lymphoid	NULL
malignancies	NULL
within	NULL
1	NULL
year	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
tumors	NULL
were	NULL
of	NULL
T	NULL
lineage	NULL
,	NULL
presumably	NULL
reflecting	NULL
the	NULL
selective	NULL
expression	NULL
of	NULL
LCK	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
.	NULL

This	NULL
contrasts	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
CD2-tal-1	NULL
mice	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
lymphoid	NULL
malignancy	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
discrepancy	NULL
might	NULL
lie	NULL
in	NULL
the	NULL
different	NULL
promoter	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
,	NULL
which	NULL
may	NULL
cause	NULL
a	NULL
different	NULL
timing	NULL
and/or	NULL
level	NULL
of	NULL
tal-1	NULL
expression	NULL
.	NULL

tal-1	NULL
protein	NULL
associates	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
with	NULL
another	NULL
nuclear	NULL
factor	NULL
in	NULL
addition	NULL
to	NULL
E2A	NULL
protein	NULL
,	NULL
Lmo-2	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Similarly	NULL
to	NULL
TAL-I	NULL
,	NULL
the	NULL
LMO-2	NULL
gene	NULL
is	NULL
rearranged	NULL
and	NULL
overexpressed	NULL
in	NULL
T	NULL
lymphoid	NULL
tumors	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
;	NULL
q11	NULL
)	NULL
(	NULL
36-38	NULL
)	NULL
,	NULL
whereas	NULL
it	NULL
is	NULL
not	NULL
expressed	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

In	NULL
normal	NULL
tissue	NULL
development	NULL
,	NULL
Lmo-2	NULL
is	NULL
expressed	NULL
together	NULL
with	NULL
TAL-1	NULL
,	NULL
especially	NULL
in	NULL
erythroid	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
selective	NULL
expression	NULL
of	NULL
Lmo-2	NULL
in	NULL
T	NULL
cells	NULL
driven	NULL
by	NULL
the	NULL
CD2	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Representative	NULL
H	NULL
&	NULL
E	NULL
staining	NULL
of	NULL
lymphoblastic	NULL
lymphoma	NULL
in	NULL
transgenic	NULL
mice	NULL
with	NULL
the	NULL
genotype	NULL
p53	NULL
5117	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

T	NULL
LYMPHOMAS	NULL
IN	NULL
TRANSGENIC	NULL
tal-1	NULL
MICE	NULL
promoter	NULL
cassette	NULL
induces	NULL
lymphomas	NULL
(	NULL
40	NULL
)	NULL
.	NULL

It	NULL
has	NULL
,	NULL
therefore	NULL
,	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
physical	NULL
interaction	NULL
between	NULL
tal-l1	NULL
and	NULL
Lmo-2	NULL
,	NULL
which	NULL
may	NULL
be	NULL
functionally	NULL
relevant	NULL
in	NULL
normal	NULL
hematopoiesis	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
,	NULL
also	NULL
takes	NULL
place	NULL
in	NULL
tumor	NULL
cells	NULL
and	NULL
is	NULL
causal	NULL
in	NULL
the	NULL
genesis	NULL
of	NULL
tumors	NULL
;	NULL
in	NULL
fact	NULL
,	NULL
although	NULL
transgenic	NULL
CD2-tal-1	NULL
mice	NULL
do	NULL
not	NULL
develop	NULL
tumors	NULL
,	NULL
cross-breeding	NULL
of	NULL
these	NULL
animals	NULL
with	NULL
CD2-Lmo-2	NULL
mice	NULL
determine	NULL
a	NULL
shortening	NULL
of	NULL
survival	NULL
due	NULL
to	NULL
a	NULL
decrease	NULL
of	NULL
the	NULL
tumor-free	NULL
life	NULL
interval	NULL
(	NULL
41	NULL
)	NULL
.	NULL

In	NULL
this	NULL
experimental	NULL
setting	NULL
,	NULL
therefore	NULL
,	NULL
tal-1	NULL
serves	NULL
as	NULL
a	NULL
tumor	NULL
promoter	NULL
,	NULL
without	NULL
having	NULL
per	NULL
se	NULL
an	NULL
oncogenic	NULL
capacity	NULL
.	NULL

Our	NULL
data	NULL
,	NULL
in	NULL
contrast	NULL
,	NULL
show	NULL
that	NULL
tal-	NULL
1	NULL
alone	NULL
can	NULL
generate	NULL
T-cell	NULL
tumors	NULL
,	NULL
without	NULL
the	NULL
inducing	NULL
action	NULL
of	NULL
other	NULL
oncogenes	NULL
.	NULL

The	NULL
oncogenic	NULL
effect	NULL
of	NULL
TAL-1	NULL
is	NULL
strikingly	NULL
increased	NULL
when	NULL
its	NULL
ectopic	NULL
expression	NULL
takes	NULL
place	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
p53Â¢*'~	NULL
background	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
in	NULL
tal-1*'~/p53*	NULL
``	NULL
~	NULL
mice	NULL
,	NULL
the	NULL
mortality	NULL
rate	NULL
was	NULL
remarkably	NULL
enhanced	NULL
as	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
pS3*'~	NULL
mice	NULL
.	NULL

Furthermore	NULL
,	NULL
all	NULL
p53	NULL
*~	NULL
/tal-1	NULL
*~	NULL
mice	NULL
died	NULL
of	NULL
disseminated	NULL
T-cell	NULL
lymphoma	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
p53	NULL
absence	NULL
on	NULL
murine	NULL
cancerogenesis	NULL
is	NULL
well	NULL
established	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Regarding	NULL
p53	NULL
het-erozygosity	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
survival	NULL
rate	NULL
in	NULL
these	NULL
animals	NULL
,	NULL
approximately	NULL
50	NULL
%	NULL
after	NULL
80	NULL
weeks	NULL
of	NULL
age	NULL
,	NULL
is	NULL
much	NULL
higher	NULL
than	NULL
in	NULL
control	NULL
p53	NULL
*'*	NULL
mice	NULL
(	NULL
43	NULL
)	NULL
.	NULL

In	NULL
our	NULL
experiments	NULL
,	NULL
all	NULL
p53	NULL
heterozygous	NULL
mice	NULL
bearing	NULL
a	NULL
Lok-tal-1	NULL
transgene	NULL
died	NULL
by	NULL
40	NULL
weeks	NULL
of	NULL
age	NULL
,	NULL
thus	NULL
shortening	NULL
by	NULL
more	NULL
than	NULL
one-half	NULL
the	NULL
survival	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
homozygous	NULL
parental	NULL
strain	NULL
of	NULL
tal-1	NULL
mice	NULL
.	NULL

Remarkably	NULL
,	NULL
a	NULL
more	NULL
extended	NULL
survival	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
control	NULL
p53~'*	NULL
mice	NULL
.	NULL

Therefore	NULL
,	NULL
tal-1	NULL
accelerates	NULL
tumorigenicity	NULL
in	NULL
this	NULL
condition	NULL
.	NULL

A	NULL
similar	NULL
acceleration	NULL
of	NULL
tumorigenesis	NULL
,	NULL
although	NULL
relatively	NULL
reduced	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
when	NULL
pS53~'~	NULL
mice	NULL
were	NULL
crossed	NULL
with	NULL
mice	NULL
expressing	NULL
the	NULL
Wnr-/	NULL
oncogene	NULL
selectively	NULL
in	NULL
the	NULL
mammalian	NULL
gland	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
c-myc	NULL
and	NULL
raf	NULL
oncogenes	NULL
are	NULL
able	NULL
to	NULL
immortalize	NULL
hematopoietic	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p53	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Our	NULL
group	NULL
observed	NULL
that	NULL
TAL-/	NULL
gene	NULL
transfer	NULL
in	NULL
the	NULL
32D	NULL
murine	NULL
hematopoietic	NULL
progenitor	NULL
cell	NULL
line	NULL
bearing	NULL
a	NULL
temperature-sensitive	NULL
p53	NULL
gene	NULL
causes	NULL
apoptosis	NULL
at	NULL
permissive	NULL
temperatures	NULL
but	NULL
favors	NULL
cell	NULL
proliferation	NULL
upon	NULL
p53	NULL
inactivation	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
TAL-/	NULL
acts	NULL
on	NULL
im-mortalization	NULL
similarly	NULL
to	NULL
c-myc	NULL
or	NULL
other	NULL
oncogenes	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
results	NULL
show	NULL
that	NULL
tal-1	NULL
expression	NULL
in	NULL
T-cell	NULL
culture	NULL
has	NULL
an	NULL
anti-apoptotic	NULL
effect	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
in	NULL
line	NULL
with	NULL
other	NULL
obser-vations	NULL
,	NULL
which	NULL
unraveled	NULL
the	NULL
anti-apoptotic	NULL
capacity	NULL
of	NULL
tal-1	NULL
in	NULL
Jurkat	NULL
(	NULL
45	NULL
)	NULL
and	NULL
32D	NULL
(	NULL
25	NULL
)	NULL
cell	NULL
lines	NULL
and	NULL
might	NULL
also	NULL
explain	NULL
the	NULL
absence	NULL
of	NULL
hematopoietic	NULL
lineage	NULL
differentiation	NULL
in	NULL
tal-1~	NULL
embryonic	NULL
stem	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
also	NULL
suggest	NULL
that	NULL
E2A	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
T-cell	NULL
homeostasis	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
by	NULL
homologous	NULL
recombination	NULL
in	NULL
mice	NULL
that	NULL
the	NULL
Â£24	NULL
gene	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
T-cell	NULL
development	NULL
;	NULL
in	NULL
fact	NULL
,	NULL
while	NULL
B-cell	NULL
development	NULL
was	NULL
blocked	NULL
,	NULL
no	NULL
effect	NULL
was	NULL
detected	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
46	NULL
,	NULL
47	NULL
)	NULL
.	NULL

We	NULL
show	NULL
that	NULL
in	NULL
transgenic	NULL
T	NULL
cells	NULL
,	NULL
tal-1	NULL
is	NULL
part	NULL
of	NULL
a	NULL
DNA	NULL
binding	NULL
complex	NULL
that	NULL
contains	NULL
a	NULL
protein	NULL
supershifted	NULL
by	NULL
anti-E2A	NULL
antiserum	NULL
,	NULL
probably	NULL
an	NULL
E2A-related	NULL
protein	NULL
.	NULL

It	NULL
may	NULL
be	NULL
hence	NULL
speculated	NULL
that	NULL
a	NULL
gene	NULL
within	NULL
the	NULL
EZ2A	NULL
family	NULL
is	NULL
expressed	NULL
and	NULL
exerts	NULL
a	NULL
regulatory	NULL
role	NULL
in	NULL
the	NULL
proliferation-differentiation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
TAL-/	NULL
is	NULL
per	NULL
se	NULL
an	NULL
oncogene	NULL
,	NULL
which	NULL
has	NULL
a	NULL
role	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
leukemogenesis	NULL
,	NULL
rather	NULL
than	NULL
representing	NULL
in	NULL
T-ALL	NULL
a	NULL
gene	NULL
with	NULL
no	NULL
proliferative	NULL
potential	NULL
(	NULL
24	NULL
)	NULL
or	NULL
a	NULL
tumor	NULL
promoter	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
R.	NULL
Perlmutter	NULL
(	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
and	NULL
R.	NULL
Baer	NULL
(	NULL
Southwestern	NULL
University	NULL
,	NULL
Dallas	NULL
,	NULL
TX	NULL
)	NULL
for	NULL
reagents	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Cleary	NULL
,	NULL
M.	NULL
L.	NULL
Oncogenic	NULL
conversion	NULL
of	NULL
transcription	NULL
factors	NULL
by	NULL
chromosomal	NULL
trans-locations	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
:	NULL
619-622	NULL
,	NULL
1991	NULL
.	NULL

2	NULL
.	NULL

Rabbits	NULL
,	NULL
T.	NULL
H.	NULL
Chromosomal	NULL
translocations	NULL
in	NULL
human	NULL
cancer	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
372	NULL
:	NULL
143-149	NULL
,	NULL
1994	NULL
.	NULL

3	NULL
.	NULL

Begley	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Aplan	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Davey	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Nakahara	NULL
,	NULL
K.	NULL
,	NULL
Tchorz	NULL
,	NULL
K.	NULL
,	NULL
Kurtzberg	NULL
,	NULL
J.	NULL
,	NULL
Hershfield	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Haynes	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
Cohen	NULL
,	NULL
D.	NULL
I.	NULL
,	NULL
Waldmann	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Kirsh	NULL
,	NULL
I.	NULL
R.	NULL
Chromosomal	NULL
translocation	NULL
in	NULL
a	NULL
human	NULL
leukemia	NULL
stem-cell	NULL
line	NULL
disrupts	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
[	NULL
8	NULL
]	NULL
-chain	NULL
diversity	NULL
region	NULL
and	NULL
results	NULL
in	NULL
a	NULL
previously	NULL
unreported	NULL
fusion	NULL
transcript	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
,	NULL
USA	NULL
,	NULL
86	NULL
:	NULL
2031-2035	NULL
,	NULL
1989	NULL
,	NULL
4	NULL
.	NULL

Finger	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Kagan	NULL
,	NULL
G.	NULL
,	NULL
Christopher	NULL
,	NULL
C.	NULL
,	NULL
Kurtzberg	NULL
,	NULL
J.	NULL
,	NULL
Hershfield	NULL
,	NULL
M.	NULL
,	NULL
Nowell	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
and	NULL
Croce	NULL
,	NULL
C.	NULL
M.	NULL
Involvement	NULL
of	NULL
TCL-5	NULL
gene	NULL
on	NULL
human	NULL
chromosome	NULL
1	NULL
in	NULL
T-cell	NULL
leukemia	NULL
and	NULL
melanoma	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
:	NULL
5039-5043	NULL
,	NULL
1989	NULL
.	NULL

5	NULL
.	NULL

Chen	NULL
,	NULL
Q.	NULL
,	NULL
Cheng	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Tsai	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Schneider	NULL
,	NULL
N.	NULL
,	NULL
Buchanan	NULL
,	NULL
G.	NULL
,	NULL
Carroll	NULL
,	NULL
A.	NULL
,	NULL
Crist	NULL
,	NULL
W.	NULL
,	NULL
Ozanne	NULL
,	NULL
B.	NULL
,	NULL
Siciliano	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
The	NULL
tal	NULL
gene	NULL
undergoes	NULL
chromosome	NULL
translocation	NULL
in	NULL
T	NULL
cell	NULL
leukemia	NULL
and	NULL
potentially	NULL
encodes	NULL
helix-loop-helix	NULL
protein	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
9	NULL
:	NULL
415-424	NULL
,	NULL
1990	NULL
.	NULL

6	NULL
.	NULL

Murre	NULL
,	NULL
C.	NULL
,	NULL
McCaw	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
A	NULL
new	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
motif	NULL
in	NULL
immunoglobulin	NULL
enhancer	NULL
binding	NULL
,	NULL
daughter/ess	NULL
,	NULL
MyoD	NULL
,	NULL
and	NULL
myc	NULL
proteins	NULL
.	NULL

Cell	NULL
,	NULL
56	NULL
:	NULL
777-783	NULL
,	NULL
1989	NULL
.	NULL

7	NULL
.	NULL

Bernard	NULL
,	NULL
O.	NULL
,	NULL
Lecointe	NULL
,	NULL
N.	NULL
,	NULL
Jonveaux	NULL
,	NULL
P.	NULL
,	NULL
Souyri	NULL
,	NULL
M.	NULL
,	NULL
MauchauffÃ©	NULL
,	NULL
M.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Larsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Mathieu-Mahul	NULL
,	NULL
D.	NULL
Two	NULL
site-specific	NULL
deletions	NULL
and	NULL
t	NULL
(	NULL
1	NULL
;	NULL
14	NULL
)	NULL
translocation	NULL
restricted	NULL
to	NULL
human	NULL
T-cell	NULL
acute	NULL
leukemias	NULL
disrupt	NULL
the	NULL
5Â°	NULL
part	NULL
of	NULL
the	NULL
tal-/	NULL
gene	NULL
.	NULL

Oncogene	NULL
,	NULL
6	NULL
:	NULL
1477-1488	NULL
,	NULL
1991	NULL
.	NULL

8	NULL
.	NULL

Visvader	NULL
,	NULL
J.	NULL
,	NULL
Begley	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
and	NULL
Adams	NULL
,	NULL
J.	NULL
M.	NULL
Differential	NULL
expression	NULL
of	NULL
the	NULL
LYL	NULL
,	NULL
SCL	NULL
,	NULL
and	NULL
E2A	NULL
helix-loop-helix	NULL
genes	NULL
within	NULL
the	NULL
hematopoietic	NULL
system	NULL
.	NULL

Oncogene	NULL
,	NULL
6	NULL
:	NULL
187-194	NULL
,	NULL
1991	NULL
.	NULL

9	NULL
.	NULL

Bernard	NULL
,	NULL
O.	NULL
,	NULL
Azogui	NULL
,	NULL
O.	NULL
,	NULL
Lecointe	NULL
,	NULL
N.	NULL
,	NULL
Mugneret	NULL
,	NULL
F.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Larsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Mathicu-Mahul	NULL
,	NULL
D.	NULL
A	NULL
third	NULL
tal-	NULL
]	NULL
promoter	NULL
is	NULL
specifically	NULL
used	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
176	NULL
;	NULL
919-925	NULL
,	NULL
1992	NULL
.	NULL

10	NULL
.	NULL

Brown	NULL
,	NULL
L.	NULL
,	NULL
Cheng	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Chen	NULL
,	NULL
Q.	NULL
,	NULL
Siciliano	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Crist	NULL
,	NULL
W.	NULL
,	NULL
Buchanan	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
Site-specific	NULL
recombination	NULL
of	NULL
the	NULL
a/-/	NULL
gene	NULL
is	NULL
a	NULL
common	NULL
occurrence	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
9	NULL
:	NULL
3343-3351	NULL
,	NULL
1990	NULL
.	NULL

11	NULL
.	NULL

Bash	NULL
,	NULL
R.	NULL
O.	NULL
,	NULL
Hall	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Timmons	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
Crist	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Amylon	NULL
,	NULL
M.	NULL
,	NULL
Smith	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
Does	NULL
activation	NULL
of	NULL
the	NULL
TAL	NULL
]	NULL
gene	NULL
occur	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
patients	NULL
with	NULL
T-cell	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
?	NULL

A	NULL
pediatric	NULL
oncology	NULL
group	NULL
study	NULL
.	NULL

Blood	NULL
,	NULL
86	NULL
:	NULL
666-676	NULL
,	NULL
1995	NULL
.	NULL

12	NULL
.	NULL

Mouthon	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Bernard	NULL
,	NULL
O.	NULL
,	NULL
Mitjavila	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Romeo	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Vainchenker	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Mathieu-Mahul	NULL
,	NULL
D.	NULL
Expression	NULL
of	NULL
tal-1	NULL
and	NULL
GATA-binding	NULL
proteins	NULL
during	NULL
human	NULL
hematopoiesis	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
:	NULL
647-655	NULL
,	NULL
1993	NULL
.	NULL

13	NULL
.	NULL

Pulford	NULL
,	NULL
K.	NULL
,	NULL
Lecointe	NULL
,	NULL
N.	NULL
,	NULL
Leroy-Viard	NULL
,	NULL
K.	NULL
,	NULL
Jones	NULL
,	NULL
M.	NULL
,	NULL
Mathieu-Mahul	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Mason	NULL
,	NULL
D.	NULL
Y	NULL
.	NULL

Expression	NULL
of	NULL
TAL-1	NULL
proteins	NULL
in	NULL
human	NULL
tissues	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
:	NULL
675-684	NULL
,	NULL
1995	NULL
.	NULL

14	NULL
.	NULL

Condorelli	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Vitelli	NULL
,	NULL
L.	NULL
,	NULL
Valtieri	NULL
,	NULL
M.	NULL
,	NULL
Marta	NULL
,	NULL
L.	NULL
,	NULL
Montesoro	NULL
,	NULL
E.	NULL
,	NULL
Lulli	NULL
,	NULL
V.	NULL
,	NULL
Baer	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Peschle	NULL
,	NULL
C.	NULL
Coordinate	NULL
expression	NULL
and	NULL
developmental	NULL
role	NULL
of	NULL
Id2	NULL
protein	NULL
and	NULL
TAL1/E2A	NULL
heterodimer	NULL
in	NULL
erythroid	NULL
progenitor	NULL
differentiation	NULL
.	NULL

Blood	NULL
,	NULL
86	NULL
:	NULL
164-175	NULL
,	NULL
1995	NULL
.	NULL

15	NULL
.	NULL

Shivdasani	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Mayer	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
Absence	NULL
of	NULL
blood	NULL
formation	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
T-cell	NULL
leukemia	NULL
oncoprotein	NULL
tal-1/SCL	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
373	NULL
:	NULL
432-434	NULL
,	NULL
1995	NULL
.	NULL

16	NULL
.	NULL

Robb	NULL
,	NULL
L.	NULL
,	NULL
Lyons	NULL
,	NULL
I.	NULL
,	NULL
Li	NULL
,	NULL
R.	NULL
,	NULL
Hartley	NULL
,	NULL
L.	NULL
,	NULL
Kontgen	NULL
,	NULL
F.	NULL
,	NULL
Harvey	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Metcalf	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Begley	NULL
,	NULL
C.	NULL
G.	NULL
Absence	NULL
of	NULL
yolk	NULL
sac	NULL
hematopoiesis	NULL
from	NULL
mice	NULL
with	NULL
a	NULL
targeted	NULL
disruption	NULL
of	NULL
the	NULL
scl	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
;	NULL
7075-7079	NULL
,	NULL
1995	NULL
.	NULL

17	NULL
.	NULL

Porcher	NULL
,	NULL
C.	NULL
,	NULL
Swat	NULL
,	NULL
W.	NULL
,	NULL
Rockwell	NULL
,	NULL
K.	NULL
,	NULL
Fujiwara	NULL
,	NULL
Y.	NULL
,	NULL
Alt	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
and	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
The	NULL
T	NULL
cell	NULL
leukemia	NULL
oncoprotein	NULL
SCL/tall	NULL
is	NULL
essential	NULL
for	NULL
development	NULL
of	NULL
all	NULL
hematopoietic	NULL
lineages	NULL
.	NULL

Cell	NULL
,	NULL
88	NULL
:	NULL
47-57	NULL
,	NULL
1996	NULL
.	NULL

18	NULL
.	NULL

Mellentin	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
and	NULL
Cleary	NULL
,	NULL
M.	NULL
L.	NULL
Ly/-/	NULL
,	NULL
a	NULL
novel	NULL
gene	NULL
altered	NULL
by	NULL
chromosomal	NULL
translocation	NULL
in	NULL
T	NULL
cell	NULL
leukemia	NULL
,	NULL
codes	NULL
for	NULL
a	NULL
protein	NULL
with	NULL
a	NULL
helix-loop-helix	NULL
DNA	NULL
binding	NULL
motif	NULL
.	NULL

Cell	NULL
,	NULL
58	NULL
:	NULL
77-83	NULL
,	NULL
1989	NULL
.	NULL

19	NULL
.	NULL

Xia	NULL
,	NULL
Y.	NULL
,	NULL
Brown	NULL
,	NULL
L.	NULL
,	NULL
Yang	NULL
,	NULL
C.	NULL
Y.	NULL
C.	NULL
,	NULL
Tsan	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Siciliano	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Espinosa	NULL
,	NULL
R.	NULL
,	NULL
III	NULL
,	NULL
Le	NULL
Beau	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
J.	NULL
TAL2	NULL
,	NULL
a	NULL
helix-loop-helix	NULL
gene	NULL
activated	NULL
by	NULL
the	NULL
(	NULL
7:9	NULL
)	NULL
(	NULL
q34	NULL
;	NULL
q32	NULL
)	NULL
translocation	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
;	NULL
11416-11420	NULL
,	NULL
1991	NULL
.	NULL

20	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Cheng	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Chen	NULL
,	NULL
Q.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
Enhancer-binding	NULL
activity	NULL
of	NULL
the	NULL
fal-7	NULL
oncoprotein	NULL
in	NULL
association	NULL
with	NULL
the	NULL
E12/E47	NULL
helix-loop-helix	NULL
proteins	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
//	NULL
;	NULL
3037-3042	NULL
,	NULL
1991	NULL
.	NULL

21	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Huang	NULL
,	NULL
L.	NULL
,	NULL
Tsan	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Funk	NULL
,	NULL
W.	NULL
,	NULL
Wright	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Hu	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Kingston	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
Preferred	NULL
sequences	NULL
for	NULL
DNA	NULL
recognition	NULL
by	NULL
the	NULL
TAL1	NULL
helix-loop-helix	NULL
proteins	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
,	NULL
Biol	NULL
.	NULL

,	NULL
14	NULL
:	NULL
1256-1265	NULL
,	NULL
1994	NULL
.	NULL

22	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Waldman	NULL
,	NULL
L	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
Formation	NULL
of	NULL
in	NULL
vivo	NULL
complexes	NULL
between	NULL
the	NULL
TALl	NULL
and	NULL
E2A	NULL
polypeptides	NULL
in	NULL
leukemic	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
97	NULL
:	NULL
3181-3185	NULL
,	NULL
1994	NULL
.	NULL

23	NULL
.	NULL

Voronova	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
F.	NULL
The	NULL
E2A	NULL
and	NULL
tal-	NULL
I	NULL
helix-loop-helix	NULL
proteins	NULL
associate	NULL
in	NULL
vivo	NULL
and	NULL
are	NULL
modulated	NULL
by	NULL
Id	NULL
proteins	NULL
during	NULL
interleukin	NULL
6-induced	NULL
myeloid	NULL
differentiation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
97	NULL
:	NULL
5952-5956	NULL
,	NULL
1994	NULL
.	NULL

24	NULL
.	NULL

Robb	NULL
,	NULL
L.	NULL
,	NULL
Rasko	NULL
,	NULL
J.	NULL
E.	NULL
J.	NULL
,	NULL
Bath	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Strasser	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Begley	NULL
,	NULL
G.	NULL
C.	NULL
scl	NULL
,	NULL
a	NULL
gene	NULL
frequently	NULL
activated	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
,	NULL
does	NULL
not	NULL
induce	NULL
lymphomas	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Oncogene	NULL
,	NULL
70	NULL
:	NULL
205-209	NULL
,	NULL
1995	NULL
,	NULL
25	NULL
.	NULL

Condorelli	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
A.	NULL
,	NULL
Botta	NULL
,	NULL
R.	NULL
,	NULL
Facchiano	NULL
,	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Vitelli	NULL
,	NULL
L.	NULL
,	NULL
Valtieri	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Peschle	NULL
,	NULL
C.	NULL
Ectopic	NULL
tal-1	NULL
expression	NULL
in	NULL
myeloid	NULL
precursors	NULL
and	NULL
nonhemato-poietic	NULL
cells	NULL
lines	NULL
:	NULL
proliferative/anti-apoptotic	NULL
effects	NULL
coupled	NULL
with	NULL
differentiation	NULL
blockade	NULL
,	NULL
submitted	NULL
for	NULL
publication	NULL
.	NULL

26	NULL
.	NULL

Chaffin	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Beals	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Wilkie	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Forbush	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Simon	NULL
,	NULL
M.	NULL
L	NULL
,	NULL
and	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
Dissection	NULL
of	NULL
thymocyte	NULL
signaling	NULL
pathways	NULL
by	NULL
in	NULL
vivo	NULL
expression	NULL
of	NULL
pertussis	NULL
toxin	NULL
ADP	NULL
-ribosyltransferase	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
9	NULL
:	NULL
3821-3829	NULL
,	NULL
1990	NULL
.	NULL

27	NULL
.	NULL

Hogan	NULL
,	NULL
B.	NULL
,	NULL
Constantini	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Lacy	NULL
,	NULL
E.	NULL
Manipulating	NULL
the	NULL
Mouse	NULL
Embryo	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
:	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
1996	NULL
.	NULL

28	NULL
.	NULL

Bind	NULL
]	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Warnke	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

Advantages	NULL
of	NULL
detecting	NULL
monoclonal	NULL
antibody	NULL
binding	NULL
to	NULL
tissue	NULL
sections	NULL
with	NULL
biotin	NULL
and	NULL
avidin	NULL
reagents	NULL
in	NULL
coplin	NULL
jars	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
.	NULL

Pathol	NULL
.	NULL

,	NULL
85	NULL
:	NULL
490-493	NULL
,	NULL
1986	NULL
.	NULL

29	NULL
.	NULL

Sentman	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Shutter	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Hockenbery	NULL
,	NULL
D.	NULL
,	NULL
Kanagawa	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
Korsmeyer	NULL
,	NULL
S.	NULL
J.	NULL
bel-2	NULL
inhibits	NULL
multiple	NULL
forms	NULL
of	NULL
apoptosis	NULL
by	NULL
not	NULL
negative	NULL
selection	NULL
in	NULL
thymocytes	NULL
.	NULL

Cell	NULL
,	NULL
67	NULL
:	NULL
879-888	NULL
,	NULL
1991	NULL
.	NULL

5118	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

T	NULL
LYMPHOMAS	NULL
IN	NULL
TRANSGENIC	NULL
(	NULL
al-1	NULL
MICE	NULL
Reynolds	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Lesley	NULL
,	NULL
J.	NULL
,	NULL
Trotter	NULL
,	NULL
J.	NULL
,	NULL
Schulte	NULL
,	NULL
R.	NULL
,	NULL
Hyman	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Sefton	NULL
,	NULL
B.	NULL
M.	NULL
Changes	NULL
in	NULL
the	NULL
relative	NULL
abundance	NULL
of	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
Ick	NULL
mRNA	NULL
transcripts	NULL
suggest	NULL
differential	NULL
promoter	NULL
usage	NULL
during	NULL
T-cell	NULL
development	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
70	NULL
:	NULL
4266-4270	NULL
,	NULL
1990	NULL
.	NULL

Wildin	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Garvin	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Pawar	NULL
,	NULL
S.	NULL
,	NULL
Lewis	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Abraham	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Forbush	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Ziegler	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Allen	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
Developmental	NULL
regulation	NULL
of	NULL
Ick	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
173	NULL
:	NULL
383-393	NULL
,	NULL
1991	NULL
.	NULL

Metz	NULL
,	NULL
T.	NULL
,	NULL
Harris	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
Adams	NULL
,	NULL
J.	NULL
M.	NULL
Absence	NULL
of	NULL
p53	NULL
allows	NULL
direct	NULL
immortal-ization	NULL
of	NULL
hematopoietic	NULL
cells	NULL
by	NULL
the	NULL
myc	NULL
and	NULL
raf	NULL
oncogenes	NULL
.	NULL

Cell	NULL
,	NULL
82	NULL
:	NULL
29-36	NULL
,	NULL
1995	NULL
.	NULL

Soddu	NULL
,	NULL
S.	NULL
,	NULL
Blandino	NULL
,	NULL
G.	NULL
,	NULL
Scardigli	NULL
,	NULL
R.	NULL
,	NULL
Martinelli	NULL
,	NULL
R.	NULL
,	NULL
Rizzo	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Crescenzi	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sacchi	NULL
,	NULL
A.	NULL
Wild-type	NULL
p53	NULL
induces	NULL
diverse	NULL
effects	NULL
in	NULL
32D	NULL
cells	NULL
expressing	NULL
different	NULL
oncogenes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
76	NULL
;	NULL
487-495	NULL
,	NULL
1996	NULL
.	NULL

Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
Osada	NULL
,	NULL
H.	NULL
,	NULL
Warren	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Forster	NULL
,	NULL
A.	NULL
,	NULL
Li	NULL
,	NULL
J.	NULL
,	NULL
Baer	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Rabbits	NULL
,	NULL
T.	NULL
H.	NULL
The	NULL
LIM	NULL
protein	NULL
RBTN2	NULL
and	NULL
the	NULL
basic	NULL
helix-loop-helix	NULL
protein	NULL
TAL	NULL
1	NULL
are	NULL
present	NULL
in	NULL
a	NULL
complex	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
97	NULL
;	NULL
8617-8621	NULL
,	NULL
1994	NULL
,	NULL
Waldman	NULL
,	NULL
I.	NULL
,	NULL
Li	NULL
,	NULL
J.	NULL
,	NULL
Bash	NULL
,	NULL
R.	NULL
O.	NULL
,	NULL
Forster	NULL
,	NULL
A.	NULL
,	NULL
Osada	NULL
,	NULL
H.	NULL
,	NULL
Rabbitts	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
and	NULL
Baer	NULL
,	NULL
R.	NULL
Specific	NULL
in	NULL
vivo	NULL
association	NULL
between	NULL
the	NULL
bHLH	NULL
and	NULL
LIM	NULL
proteins	NULL
implicated	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
73	NULL
:	NULL
4831-4839	NULL
,	NULL
1994	NULL
.	NULL

Royer-Pokora	NULL
,	NULL
B.	NULL
,	NULL
Fleischer	NULL
,	NULL
B.	NULL
,	NULL
Ragg	NULL
,	NULL
S.	NULL
,	NULL
Loos	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
D.	NULL
Molecular	NULL
cloning	NULL
of	NULL
the	NULL
translocation	NULL
breakpoint	NULL
in	NULL
T-ALL	NULL
11	NULL
;	NULL
14	NULL
(	NULL
pl3	NULL
:	NULL
q11	NULL
)	NULL
:	NULL
genomic	NULL
map	NULL
of	NULL
TCR	NULL
alpha	NULL
and	NULL
delta	NULL
region	NULL
on	NULL
chromosome	NULL
14q11	NULL
and	NULL
long-range	NULL
map	NULL
of	NULL
region	NULL
l1p13	NULL
.	NULL

Hum	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
82	NULL
:	NULL
264-270	NULL
,	NULL
1989	NULL
.	NULL

Royer-Pokora	NULL
,	NULL
B.	NULL
,	NULL
Loos	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Ludwig	NULL
,	NULL
W.	NULL
D.	NULL
TTG-2	NULL
,	NULL
a	NULL
new	NULL
gene	NULL
encoding	NULL
a	NULL
cysteine-rich	NULL
protein	NULL
with	NULL
the	NULL
LIM	NULL
motif	NULL
,	NULL
is	NULL
overexpressed	NULL
in	NULL
acute	NULL
T-cell	NULL
leukaemia	NULL
with	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
:	NULL
;	NULL
q11	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
6	NULL
:	NULL
1887-1893	NULL
,	NULL
1991	NULL
.	NULL

Boehm	NULL
,	NULL
T.	NULL
,	NULL
Foroni	NULL
,	NULL
L.	NULL
,	NULL
Kaneko	NULL
,	NULL
Y.	NULL
,	NULL
Perutz	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
Rabbits	NULL
,	NULL
T.	NULL
H.	NULL
The	NULL
rhombotin	NULL
family	NULL
of	NULL
cysteine-rich	NULL
LIM-domain	NULL
oncogenes	NULL
:	NULL
distinct	NULL
members	NULL
are	NULL
involved	NULL
in	NULL
T-cell	NULL
translocations	NULL
to	NULL
human	NULL
chromosomes	NULL
11p15	NULL
and	NULL
11p13	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
:	NULL
4367-4371	NULL
,	NULL
1991	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

5119	NULL
Warren	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Colledge	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Carlton	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Evans	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Smith	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Rabbits	NULL
,	NULL
T.	NULL
H.	NULL
The	NULL
oncogenic	NULL
cysteine-rich	NULL
LIM	NULL
domain	NULL
protein	NULL
rbtn2	NULL
is	NULL
essential	NULL
for	NULL
erythroid	NULL
development	NULL
.	NULL

Cell	NULL
,	NULL
78	NULL
:	NULL
45-57	NULL
,	NULL
1994	NULL
,	NULL
Larson	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Fisch	NULL
,	NULL
P.	NULL
,	NULL
Larson	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Lavenir	NULL
,	NULL
I.	NULL
,	NULL
Langford	NULL
,	NULL
T.	NULL
,	NULL
King	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Rabbitts	NULL
,	NULL
T.	NULL
H.	NULL
T	NULL
cell	NULL
tumours	NULL
of	NULL
disparate	NULL
phenotype	NULL
in	NULL
mice	NULL
transgenic	NULL
for	NULL
Rbtn-2	NULL
.	NULL

Oncogene	NULL
,	NULL
9	NULL
:	NULL
3675-3681	NULL
,	NULL
1994	NULL
.	NULL

Larson	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Lavenir	NULL
,	NULL
I.	NULL
,	NULL
Larson	NULL
.	NULL

T.	NULL
A..	NULL
Baer	NULL
,	NULL
R.	NULL
,	NULL
Warren	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Waldman	NULL
,	NULL
I.	NULL
,	NULL
Nottage	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Rabbitts	NULL
,	NULL
T.	NULL
H.	NULL
Protein	NULL
dimerization	NULL
between	NULL
Lmo2	NULL
(	NULL
Rbtn2	NULL
)	NULL
and	NULL
Tall	NULL
alters	NULL
thymocyte	NULL
development	NULL
and	NULL
potentiates	NULL
T	NULL
cell	NULL
tumorigenesis	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
75	NULL
:	NULL
1021-1027	NULL
,	NULL
1996	NULL
.	NULL

Donehower	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Harvey	NULL
,	NULL
M.	NULL
,	NULL
Slagle	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
McArthur	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Montgomery	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Butel	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Bradley	NULL
,	NULL
A	NULL
.	NULL

Mice	NULL
deficient	NULL
for	NULL
p53	NULL
are	NULL
developmentally	NULL
normal	NULL
but	NULL
susceptible	NULL
to	NULL
spontaneous	NULL
tumours	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
356	NULL
:	NULL
215-221	NULL
,	NULL
1992	NULL
.	NULL

Harvey	NULL
,	NULL
M.	NULL
,	NULL
McArthur	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Montgomery	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Butel	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Bradley	NULL
,	NULL
A..	NULL
and	NULL
Donehower	NULL
,	NULL
L.	NULL
A.	NULL
Spontaneous	NULL
and	NULL
carcinogen-induced	NULL
tumorigenesis	NULL
in	NULL
p53-defi-cient	NULL
mice	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
5	NULL
:	NULL
225-229	NULL
,	NULL
1993.	NULL
.	NULL

Donehower	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Godley	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Aldaz	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Pyle	NULL
,	NULL
R.	NULL
,	NULL
Shi	NULL
,	NULL
Y.	NULL
P.	NULL
,	NULL
Pinkel	NULL
,	NULL
D.	NULL
,	NULL
Gray	NULL
,	NULL
J.	NULL
,	NULL
Bradley	NULL
,	NULL
A.	NULL
,	NULL
Medina	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Varmus	NULL
,	NULL
H.	NULL
E.	NULL
Deficiency	NULL
of	NULL
p53	NULL
accelerates	NULL
mammary	NULL
tumorigenesis	NULL
in	NULL
Wnt-1	NULL
transgenic	NULL
mice	NULL
and	NULL
promotes	NULL
chromosomal	NULL
in-stability	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
:	NULL
882-895	NULL
,	NULL
1995	NULL
.	NULL

Leroy-Viard	NULL
,	NULL
K.	NULL
,	NULL
Vinit	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Lecointe	NULL
,	NULL
N.	NULL
,	NULL
Jouault	NULL
,	NULL
H.	NULL
,	NULL
Hibner	NULL
,	NULL
U.	NULL
,	NULL
Romeo	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
and	NULL
Mathicu-Mahul	NULL
,	NULL
D.	NULL
Loss	NULL
of	NULL
TAL-I	NULL
protein	NULL
activity	NULL
induces	NULL
premature	NULL
apoptosis	NULL
of	NULL
Jurkat	NULL
leukemic	NULL
T	NULL
cells	NULL
upon	NULL
medium	NULL
depletion	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
74	NULL
:	NULL
2341-2349	NULL
,	NULL
1995	NULL
.	NULL

Bain	NULL
,	NULL
G.	NULL
,	NULL
Maandag	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Izon	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Amsen	NULL
,	NULL
D.	NULL
,	NULL
Kruisbeek	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Weintraub	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
Krop	NULL
,	NULL
L..	NULL
Schlissel	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Feeney	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
van	NULL
Roon	NULL
,	NULL
M.	NULL
E2A	NULL
proteins	NULL
are	NULL
required	NULL
for	NULL
proper	NULL
B	NULL
cell	NULL
development	NULL
and	NULL
initiation	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
rearrangements	NULL
.	NULL

Cell	NULL
,	NULL
79	NULL
:	NULL
885-892	NULL
,	NULL
1994	NULL
.	NULL

Zhuang	NULL
,	NULL
Y.	NULL
,	NULL
Soriano	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Weintraub	NULL
,	NULL
H.	NULL
The	NULL
helix-loop-helix	NULL
gene	NULL
Â£24	NULL
is	NULL
required	NULL
for	NULL
B	NULL
cell	NULL
formation	NULL
.	NULL

Cell	NULL
,	NULL
79	NULL
:	NULL
875-884	NULL
,	NULL
1994	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
T-Cell-directed	NULL
TAL-1	NULL
Expression	NULL
Induces	NULL
T-Cell	NULL
Malignancies	NULL
in	NULL
Transgenic	NULL
Mice	NULL
G.	NULL
L.	NULL
Condorelli	NULL
,	NULL
F.	NULL
Facchiano	NULL
,	NULL
M.	NULL
Valtieri	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56:5113-5119	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/56/22/5113	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/56/22/5113	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1996	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

